Clinical trials of stent

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
drug-eluting stents vs bare-metal stent			
DEDICATION , 2008 [NCT00192868] n=313/313 follow-up: 8 mo (15 mo, 3y)	DES currently used with or without distal protection versus BMS with or without distal protection	patients referred within 12 hours from symptom onset of an ST-elevation myocardial infarction	Factorial plan open Denmark.
PASEO , 2009 n=180/90 follow-up: 4.3 years	paclitaxel-eluting stents and sirolimus-eluting stents versus bare metal stent	patients with ST-elevation myocardial infarction within 12 hours from symptom onset	Parallel groups open
paclitaxel eluting stent vs bare-metal stent			
HAAMU-STENT , 2006 *unpublished* n=70/75 follow-up: 12 months	Taxus Express versus Bare-metal-stent	AMI - STEMI patients undergoing PCI	Parallel groups open Finland
HORIZONS-AMI Stent , 2008 n=2257/749 follow-up: 1 year	paclitaxel-eluting stents (Taxus) versus BMS (Express)	ST-elevation myocardial infarction	Factorial plan open
PASSION , 2006 [ISRCTN65027270] n=310/309 follow-up: 12 months (5y)	Taxus Express2 versus Express2 or Libert	Myocardial Infarction with ST-Segment Elevation	Parallel groups open The Netherlands
sirolimus eluting stent vs bare-metal stent			
DEBATER (SES vs BMS) , 2009 n=424/446 follow-up: 1 y	sirolimus-eluting stents versus bare-metal stents	patients undergoing PCI for STEMI withon 12 hours	Factorial plan
Daz de la Llera , 2007 n=60/54 follow-up: 1y	sirolimus-eluting stents versus uncoated stents	primary percutaneous coronary intervention for acute myocardial infarction with ST-segment elevation	Parallel groups open Spain

continued...

Trial	Treatments	Patients	Trials design and methods
MISSION , 2008 [ISRCTN62825862] n=158/152 follow-up: 12 months	Cypher versus Vision	primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h)	Parallel groups single-blind the Netherlands
SESAMI , 2007 [NCT00288210] n=160/160 follow-up: 12 months	Cypher versus BX stent, Cordis	AMI	Parallel groups open Italy
TYPHOON , 2006 [NCT00232830] n=356/359 follow-up: 12 months	Cypher or CypherSelect versus any commerciallyavailable uncoated stent	AMI	Parallel groups open Worldwide (15 countries)
systematic PCI (+stent) vs no systematic PCI			
CAPITAL AMI , 2005 n=86/84 follow-up: 6 months	TNK-facilitated angioplasty versus TNK alone	patients with high-risk ST-segment elevation myocardial infarction	Parallel groups
GRACIA-1 , 2004 n=248/251 follow-up: 12 months	angiography and intervention if indicated within 24 h of thrombolysis versus ischaemia-guided conservative approach	patients with thrombolysed STEMI (with recombinant tissue plasminogen activator)	Parallel groups
PRAGUE , 2000 n=100/99 follow-up: 12 months	thrombolysis during immediate transportation for coronary angioplasty versus thrombolysis in a community hospital	patients with acute ST elevation myocardial infarction presenting to community hospitals	
SIAM III , 2002 n=82/81 follow-up: 6 months	immediate stenting after thrombolysis versus conservative treatment	patients receiving thrombolysis in AMI (<12 h)	Parallel groups Germany
WEST , 2006 n=104/100 follow-up: 30 days	TNK and mandatory invasive study <= 24 h, including rescue PCI for reperfusion failure versus tenecteplase (TNK) and usual care	STEMI patients (>4 mm ST-elevation/deviation) within 6 h of symptom onse	Parallel groups Canada
primary stenting vs accelerated t-PA			
STAT , 2001 n=62/61 follow-up: 6 months	primary stenting versus accelerated t-PA	patients with acute ST-elevation myocardial infarction	Parallel groups open
facilitated stenting vs alteplase			

continued...

Trial	Treatments	Patients	Trials design and methods
STOPAMI 1 , 2000 n=71/69 follow-up: 6 months	stent plus abciximab versus intravenous alteplase	patients with acute myocardial infarction	Parallel groups open
primary stenting vs balloon angioplasty			
Zwolle 5 (Suryapranata) , 1998 n=112/115 follow-up: 12 months	Stent Palmaz-Schatz versus balloon angioplasty	Patients with acute myocardial infarction	Parallel groups open
FRESCO , 1998 n=75/75 follow-up: 12 months	elective stenting after successful primary PTCA versus no further intervention after successful primary PTCA	patient with successful primary PTCA	Parallel groups open
GRAMI (Rodriguez) , 1998 n=52/52 follow-up: 12 months	balloon angioplasty followed electively with Gianturco Roubin II stents versus conventional balloon angioplasty	patients with acute myocardial infarction within 24 hours after onset	Parallel groups open
PASTA (Saito) , 1999 n=67/70 follow-up: 12 months	Stent Palmaz-Schatz versus primary balloon angioplasty	patients with AMI within 12 hr from onset	Parallel groups open
stent-PAMI (Grines) , 1999 n=452/448 follow-up: 12 months	angioplasty with Stent Heparin-coated versus angioplasty alone	patients with acute myocardial infarction and with vessels suitable for stenting	Parallel groups open
STENTIM-2 (Maillard) , 2000 n=101/110 follow-up: 12 months	systematic stenting with Stent Wiktor versus conventional balloon angioplasty	patients with AMI <12 h from symptom onset, with an occluded native coronary artery	Parallel groups open
PSSAAMI (Scheller) , 2001 n=44/44 follow-up: 24 months	Stent Wiktor GX versus primary angioplasty	patients within 24 hours after the onset of acute myocardial infarction	Parallel groups open
Jaksch , 1998 n=231/231 follow-up: 65279;6 months	-	-	Parallel groups open
PRISAM (Kawashima) , 1999 n=110/112 follow-up: 65279;6 months	-	-	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
CADILLAC (no abciximab) , 2002 n=512/518 follow-up: 12 months	stenting alone with the MultiLink stent versus PTCA alone	patients with acute myocardial infarction	Parallel groups open
CADILLAC abciximab. , 2002 n=524/528 follow-up: 12 months	stenting plus abciximab therapy versus PTCA plus abciximab therapy	patients with acute myocardial infarction	Parallel groups open
ZWOLLE 6 , 2005 n=785/763 follow-up: 12 months	stenting versus balloon angioplasty	unselected patients with STEMI	Parallel groups open
STOPAMI 3 , 2004 n=305/306 follow-up: 6 months	coronary artery stenting versus PTCA	patients with AMI ineligible for thrombolysis (lack of ST-segment elevation on the electrocardiogram, late presentation >12 h after symptom onset, and contraindications to thrombolysis)	Parallel groups open
primary stenting vs immediate thrombolysis			
STOPAMI 2 , 2002 n=81/81 follow-up:	stenting combined with abciximab versus fibrinolysis by alteplase combined with abciximab	patients with acute myocardial infarction within 12 h of onset of symptoms	Parallel groups open
sirolimus eluting stent vs paclitaxel eluting stent			
Di Lorenzo et al. , 2005 *unpublished* n=90/90 follow-up:	sirolimus versus paclitaxel	ST-segment elevation myocardial infarction	Parallel groups open
Juwana , 2009 [ISRCTN90526229] n=196/201 follow-up: 9 months (12 months)	sirolimus coated Cypher stent versus paclitaxel coated Taxus stent	patients with STEMI undergoing primary PCI	Parallel groups open The Netherlands
PROSIT , 2006 n=154/154 follow-up: 1 year	SES Cordis versus PES Boston Scientific	AMI or persistent ischaemia 12-24h	Parallel groups open Korea
zotarolimus eluting stent vs paclitaxel eluting stent			
ZEST AMI (vs PES) , 2009 [NCT00422565] n=108/110 follow-up: 1 year (mean)	zotarolimus-eluting stent (Endeavor) versus paclitaxel-eluting stent (Taxus Libert)	Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours	open Korea

continued...

Trial	Treatments	Patients	Trials design and methods
zotarolimus eluting stent vs sirolimus eluting stent			
ZEST AMI (vs SES) , 2009 [NCT00422565] n=108/110 follow-up: 1 year (mean)	zotarolimus-eluting stent (Endeavor) versus sirolimus-eluting stents (Cypher)	Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours	Parallel groups open Korea

More details and results :

- myocardial revascularization for acute myocardial infarction in all type of patients at http://www.trialresultscenter.org/go-Q129
- PCI for acute myocardial infarction in all type of patients at http://www.trialresultscenter.org/go-Q246
- myocardial revascularization for acute myocardial infarction in patient ineligible for thrombolysis at http://www.trialresultscenter.org/go-Q254
- PCI for acute myocardial infarction in patient ineligible for thrombolysis at http://www.trialresultscenter.org/go-Q255

References

DEDICATION, 2008:

Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klvgaard L, Kaltoft A, Andersen B, Thuesen H, Engstrm T, Btker HE, Saunamki K, Krusell LR, Jrgensen E, Hansen HH, Christiansen EH, Ravkilde J, Kber L, Kofoed KF, Terkelsen CJ, Lassen JF Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008 Sep 9;118:1155-62 [18725489]

Kaltoft A, Kelbk H, Thuesen L, Lassen JF, Clemmensen P, Klvgaard L, Engstrm T, Btker HE, Saunamki K, Krusell LR, Jrgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Kber L, Kofoed KF, Terkelsen CJ, Helqvist S Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Follow-Up of the Randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010 Jun 14;: [20688033] 10.1016/j.jacc.2010.05.009

PASEO, 2009:

Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv 2009 Jun;2:515-23 [19539255]

Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation 2009;120:964-72 [19720939]

HAAMU-STENT, 2006:

unpublished

Tierala I, Syvaenne M, Kupari M Randomised comparison of apaclitaxel-eluting and a bare metal stent in STEMI-PCI. TheHAAMU-STENT-study Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics; Washington, DC;Oct 2227, 2006. Abstract 178.

HORIZONS-AMI Stent, 2008:

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011 Jun 25;377:2193-2204 [21665265] 10.1016/S0140-6736(11)60764-2

PASSION, 2006:

Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13 [16971717]

Dirksen MT, Vink MA, Suttorp MJ, Tijssen JG, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ EuroIntervention 2008 May;4:64-70 [19112781]

DEBATER (SES vs BMS), 2009:

Daz de la Llera, 2007:

Daz de la Llera LS, Ballesteros S, Nevado J, Fernndez M, Villa M, Snchez A, Retegui G, Garca D, Martnez A Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007;154:164.e1-6 [17584571]

MISSION, 2008:

van der Hoeven BL, Liem S, Jukema JW, et al. Prospectiverandomised trial to evaluate the effi cacy and safety of drug-elutingstents versus barem-metal stents for the treatment of acutemyocardial infarction (the MISSION! intervention study) AnnualScientifi c Meeting of the American Heart Association. Chicago, IL,USA; Nov 1215, 2006.

van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008 Feb 12;51:618-26 [18261680]

SESAMI, 2007:

Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007;49:1924-30 [17498576]

Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli R Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Results of the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010 Feb 23;55:810-814 [20170821] 10.1016/j.jacc.2009.09.046

TYPHOON, 2006:

Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104 [16971716]

CAPITAL AMI, 2005:

Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, Maloney J, McKibbin T, Quinn B, Beanlands RS, Glover C, Marquis JF, O'Brien ER, Williams WL, Higginson LA Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46:417-24 [16053952]

GRACIA-1, 2004:

Fernandez-Avils F, Alonso JJ, Castro-Beiras A, Vzquez N, Blanco J, Alonso-Briales J, Lpez-Mesa J, Fernndez-Vazquez F, Calvo I, Martnez-Elbal L, San Romn JA, Ramos B Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment

elevation (GRACIA-1): a randomised controlled trial. Lancet 2004;364:1045-53 [15380963]

PRAGUE, 2000:

Widimsk P, Groch L, Zelzko M, Aschermann M, Bednr F, Suryapranata H Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000;21:823-31 [10781354]

Bednr F, Widimsk P, Krupicka J, Groch L, Aschermann M, Zelzko M Interhospital transport for primary angioplasty improves the long-term outcome of acute myocardial infarction compared with immediate thrombolysis in the nearest hospital (one-year follow-up of the PRAGUE-1 study). Can J Cardiol 2003;19:1133-7 [14532938]

SIAM III, 2002:

Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, Winter H, Nickenig G, Bhm M Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003;42:634-41 [12932593]

WEST, 2006:

Armstrong PW A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27:1530-8 [16757491]

STAT, 2001:

Le May MR, Labinaz M, Davies RF, Marquis JF, Larame LA, O'Brien ER, Williams WL, Beanlands RS, Nichol G, Higginson LA Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001;37:985-91 [11263625]

STOPAMI 1, 2000:

Schmig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000;343:385-91 [10933737]

Zwolle 5 (Suryapranata), 1998:

Suryapranata H, van 't Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998;97:2502-5 [9657469]

FRESCO, 1998:

Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234-9 [9581713]

GRAMI (Rodriguez), 1998:

Rodrguez A, Bernardi V, Fernndez M, Mauvecn C, Ayala F, Santaera O, Martnez J, Mele E, Roubin GS, Palacios I, Ambrose JA In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. Am J Cardiol 1998;81:1286-91 [9631964]

PASTA (Saito), 1999:

Saito S, Hosokawa G, Tanaka S, Nakamura S Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Interv 1999;48:262-8 [10525224]

stent-PAMI (Grines), 1999:

Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949-56 [10607811]

STENTIM-2 (Maillard), 2000:

Maillard L, Hamon M, Khalife K, Steg PG, Beygui F, Guermonprez JL, Spaulding CM, Boulenc JM, Lipiecki J, Lafont A, Brunel P, Grollier G, Koning R, Coste P, Favereau X, Lancelin B, Van Belle E, Serruys P, Monassier JP, Raynaud P A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. J Am Coll Cardiol 2000;35:1729-36 [10841218]

PSSAAMI (Scheller), 2001:

Scheller B, Hennen B, Severin-Kneib S, Ozbek C, Schieffer H, Markwirth T Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction. Am J Med 2001;110:1-6 [11152857]

Jaksch, 1998:

Jaksch R, Niehus R, Knobloch W, Schiele T. $s_ec = PTCAversusstentinginacutemyocardialinfarctione/pjEurHeartJ.1998; 19 : 1341x - xbitm$

PRISAM (Kawashima), 1999:

Kawashima A, Ueda K, Nishida Y, et al.ag Quantitative angiographic analysis of restenosis of primary stenting using Wiktor stent for acute myocardial infarction: results from a multicenter randomized PRISAM study.6 Circulation. 1999;100(suppl 1):I856..ag

CADILLAC (no abciximab), 2002:

Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66 [11919304]

CADILLAC abciximab., 2002:

Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66 [11919304]

ZWOLLE 6, 2005:

Suryapranata H, De Luca G, van 't Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosselink AT, Zijlstra F, de Boer MJ Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart 2005;91:641-5 [15831652]

De Luca G, Suryapranata H, van't Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosselink AT, de Boer MJ Routine stenting vs. balloon angioplasty in ST-segment elevation myocardial infarction due to proximal left anterior descending coronary artery occlusion. J Cardiovasc Med (Hagerstown) 2009 Jan;10:22-6 [19145115]

STOPAMI 3, 2004:

Kastrati A, Mehilli J, Nekolla S, Bollwein H, Martinoff S, Pache J, Schhlen H, Seyfarth M, Gawaz M, Neumann FJ, Dirschinger J, Schwaiger M, Schmig A A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. J Am Coll Cardiol 2004;43:734-41 [14998609]

STOPAMI 2, 2002:

Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, Martinoff S, Neumann FJ, Nekolla S, Blasini R, Seyfarth M, Schwaiger M, Schmig A Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 2002;359:920-5 [11918909]

Di Lorenzo et al., 2005:

unpublished

Di Lorenzo E, Varricchio A, Lanzillo T, et al. Paclitaxel and sirolimusstent implantation in patients with acute myocardial infarction (abstr) Circulation 2005;112:U538

Juwana, 2009:

Juwana YB, Suryapranata H, Ottervanger JP, De Luca G, van't Hof AW, Dambrink JH, de Boer MJ, Gosselink AT, Hoorntje JC Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 2009;104:205-9 [19576348]

PROSIT, 2006:

Lee JH, Kim HS, Lee SW, et al. Prospective randomized trial of asirolimus eluting versus a paclitaxel eluting stent for the treatmentof acute ST-elevation myocardial infarction Annual Scientifi cMeeting of the American College of Cardiology; Atlanta, GA, USA;March 1114, 2006.

Kornowski R Drug-eluting stents in ST elevation myocardial infarction: In light of the PROSIT trial. Catheter Cardiovasc Interv 2008 Jul 1;72:33-5 [18561153]

Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, Cho Y, Lee N, Rhee KS, Ko JK, Seong IW Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv 2008 Jul 1;72:25-32 [18412270]

ZEST AMI (vs PES), 2009:

Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;104:1370-6 [19892052]

ZEST AMI (vs SES), 2009:

Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;104:1370-6 [19892052]

2 stable angina

Trial	Treatments	Patients	Trials design and methods
stent vs balloon angioplasty			
Lincoff (EPISTENT) , 1999 [NCT00271401] n=794/796 follow-up: 6 months	stent followed by aspirin 325 mg, abciximab versus balloon angioplasty followed by aspirin 325 mg, abciximab	patients with ischaemic heart disease and suitable coronary-artery lesions	Parallel groups open USA, Canada
Hoher , 1999 n=42/43 follow-up: 6 months	Wiktor versus PTCA alone	patients with a thrombolysis in myocardial infarction grade 0 chronic coronary occlusion	Parallel groups open
Serruys Benestent , 1994 n=262/258 follow-up: 7 months	Palmaz-Schatz versus balloon angioplasty, aspirin 250-500 mg + dipyridamole 75 mgx3	Stable angina	Parallel groups Open Europe
Fischman STRESS , 1994 n=205/202 follow-up: 6 months	Palmaz-Schatz versus ballon angioplasty aspirin, dipyridamol	Stable angina	Parallel groups Open USA
Eeckout , 1996 n=42/42 follow-up: 6 months	Wiktor stent implantation versus conventional balloon angioplasty	Stable angina	Parallel groups open
Sirnes , 1996 n=58/59 follow-up: 6 months	Palmaz-Schatz versus PTCA alone	patients with a satisfactory result after successful recanalization by PTCA of a chronic coronary occlusion	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
Versaci , 1997 n=60/60 follow-up: 12 months	Palmaz-Schatz versus standard coronary angioplasty, aspirin and diltiazem indefinitely	patients with isolated stenosis of the proximal left anterior descending coronary artery	Parallel groups open Italy
Savage , 1998 n=108/107 follow-up: 6 months	Palmaz-Schatz stent versus standard balloon angioplasty	patients with new lesions in aortocoronary-venous bypass grafts	Parallel groups open
Erbel , 1998 n=191/192 follow-up: 6 months	Palmaz-Schatz versus standard balloon angioplasty	patients with clinical and angiographic evidence of restenosis after at least one balloon angioplasty	Parallel groups open
Rubartelli , 1998 n=56/54 follow-up: 9 months	Palmaz-Schatz stent implantation versus PTCA alone	patients with recanalized total occlusion	Parallel groups open
Hancock , 1998 n=30/30 follow-up: 6 months	Palmaz-Schatz versus angioplasty alone	patients with a total coronary occlusion successfully treated by PTCA	Parallel groups open
Serruys Benestent 2 , 1998 n=414/413 follow-up: 12 months	Heparin-coated Palmaz-Schatz versus ballon angioplastyaspirin >=100mg 6 month	Stable and unstable angina	Parallel groups Open Europe
Rodriguez , 1998 n=57/59 follow-up: 6 months	stent versus optimal PTCA	patients obtaining a good immediate angiographic result after percutaneous transluminal coronary angioplasty	Parallel groups open
Sievert , 1999 n=55/55 follow-up: 4 months	stent implantation versus angioplasty alone	Stable angina	Parallel groups open
Betriu , 1999 n=229/223 follow-up: 6 months (4y)	Palmaz-Schatz versus standard balloon angioplasty	Stable and unstable angina	Parallel groups open
Buller , 1999 n=202/208 follow-up: 6 months	Heparin-coated Palmaz-Schatz versus PTCA	patients with nonacute native coronary occlusions	Parallel groups open
Serruys , 2000 n=97/511 follow-up: 12 months	primary stenting versus balloon angioplasty	patients scheduled for single-vessel angioplasty	Parallel groups open
Di Marlo , 2000 n=370/365 follow-up: 12 months	elective stent implantation versus guided PTCA	Stable and unstable angina; no AMI inprevious 24 h	Parallel groups open
Kastrati , 2000 n=204/200 follow-up: 7 months	Multilink versus PTCA	Patients with symptomatic coronary artery disease with lesions situated in native coronary vessels between 2 and 2.8 mm in size	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
Witkowski , 2000 n=192/196 follow-up: 6 months	Palmaz-Schatz stent versus angioplasty	Symptomatic CAD; no AMI in previous 14 d	Parallel groups open
Lafont , 2000 n=125/126 follow-up: 6 months	systematic stenting versus provisional stenting (group 1, in which stenting was performed if postangioplasty coronary velocity reserve was <2.2 and/or residual stenosis >or =35% or as bail-out)	patients undergoing elective coronary angioplasty	Parallel groups open
Fluck , 2000 n=154/146 follow-up: 12 months	Wiktor stent versus balloon angioplasty	Symptomatic CAD; no AMI in previous 7 d	Parallel groups open
Dangas , 2000 n=31/66 follow-up: 8 months	elective stenting (Palmaz-Schatz stent) versus PTCA with prolonged perfusion balloon inflation	patients with discrete, de novo lesions in native coronary arteries >or =3 mm in diameter	Parallel groups open
Weaver , 2000 n=229/248 follow-up: 6 months	routine stent implantation (Palmaz-Schatz) versus balloon angioplasty and provisional stenting	patients undergoing single-vessel coronary angioplasty	Parallel groups open
Lotan , 2000 n=48/48 follow-up: 6 months	stent implantation (AVE Micro Stent) versus no further treatment	with total coronary artery occlusions who had an optimal PTCA result	Parallel groups open
Park , 2000 n=60/60 follow-up: 6 months (16 m)	elective stent placement (7-cell NIR stent) versus balloon angioplasty	patients with lesions in small coronary arteries (de novo, non-ostial lesion and reference diameter <3 mm)	Parallel groups open
Koning , 2001 n=192/189 follow-up: 6 months	stent implantation (beStent Small) versus standard balloon angioplasty	symptomatic patients with de novo focal lesion located on a small coronary segment vessel (<3 mm)	Parallel groups open
Doucet , 2001 n=169/182 follow-up: 6 months	stent implantation (beStent-Artist) versus angioplasty alone	symptomatic patients needing dilatation of 1 native coronary vessel between 2.3 and 2.9 mm in size	Parallel groups open
Moer , 2001 n=74/71 follow-up: 6 months	elective stenting treatment with the heparin (Hepamed)-coated beStent versus PTCA	patients with stable or unstable angina	Parallel groups open
dactinomycin eluting stent vs bare-metal stent			
ACTION , 2004 n=241/119 follow-up: 6 months	Multilink Tetra stent versus uncoated Multilink Tetra stent	Patients with stable angina pectoris orsilent ischemia and a single de novo lesion in a nativecoronary artery >=3.0 mm and <=4.0 mm in diameter thatcould be covered by an 18-mm stent	Parallel groups single-blind worldwide

continued...

Trial	Treatments	Patients	Trials design and methods
everolimus eluting stent vs bare-metal stent			
FUTURE I , 2004 n=27/15 follow-up: 12 months	everolimus coated S-Stent versus S-Stent	de novo coronary lesions	Parallel groups single-blind Germany
FUTURE II , 2006 *unpublished* n=43/21 follow-up: 6 months	CHAMPION versus bare-metal stent	Patients with de novo lesions in vessels with a reference diameter of 2.75-4.0 mm and length </= 18 mm	Parallel groups double-blind
SPIRIT I , 2005 [NCT00180453] n=28/32 follow-up: 6 months (5yr)	everolimus eluting sent, XIENCE versus bare etal stent, MULTI-LINK VISION	patients with de novo native coronary artery lesions	Parallel groups single-blind
paclitaxel eluting stent vs bare-metal stent			
SCORE , 2004 n=126/140 follow-up: 12 months	QuaDDS stents (paclitaxel) versus uncoated control stents	patients with focal, de novo coronary lesions	Parallel groups open Worldwide
TAXUS I , 2003 n=31/30 follow-up: 12 months	TAXUS NIR versus NIR stent	Stable or unstable AP, silent ischaemia; single de novo or restenotic coronary lesions	Parallel groups double-blind Germany
TAXUS II , 2003 [NCT00299026] n=266/270 follow-up: 12 months	TAXUS versus NIR stent	Stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99% ,	Parallel groups double-blind Global
TAXUS IV , 2004 [NCT00292474] n=662/652 follow-up: 9 months	TAXUS versus EXPRESS	Stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)	Parallel groups double-blind United States
TAXUS V (all patients) , 2005 [NCT00301522] n=577/579 follow-up: 9 months	TAXUS versus bare metal EXPRESS-2	Stable or unstable AP, silent ischaemia with single coronary artery stenosis including complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)	Parallel groups double-blind United States
TAXUS VI , 2005 [NCT00297804] n=219/227 follow-up: 9 months (2y)	TAXUS versus Express2 stent	Stable or unstable AP, silent ischaemia with long, complex coronary artery lesions	Parallel groups double-blind Europe

continued...

Trial	Treatments	Patients	Trials design and methods
BASKET-SAVAGE *ongoing* [NCT00595647] n=NA follow-up:	Taxus versus Libert	percutaneous coronary interventions of saphenous vein grafts	open
paclitaxel, non-polymeric eluting stent vs bare-metal stent			
ASPECT , 2003 [NCT00196079] n=117/58 follow-up: 6 months	coated Supra-G stent versus Supra-G stent	patientswith discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter)	Parallel groups double-blind
DELIVER , 2004 n=524/519 follow-up: 9 months	non-polymer-based paclitaxel-coated ACHIEVE stent versus stainless steel Multi-Link (ML) PENTA stent	patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels	Parallel groups single-blind US
ELUTES , 2004 n=152/38 follow-up: 12 months	coated V-Flex Plus versus V-Flex Plus	single de novo type A or type B1 lesions 15 mm length in a nativecoronary artery	Parallel groups open Europe
PATENCY , 2002 *unpublished* n=24/26 follow-up: 9 months	Logic PTX paclitaxel Eluting CoronaryStents versus uncoated control stents	Patients with de novo lesions of 2.7- to 4.0-mm diameter and 25-mm length received 3.0, 3.5, or 4.0 mm 10- or 15-mm	Parallel groups double blind
sirolimus eluting stent vs bare-metal stent			
C-SIRIUS , 2004 [NCT00381420] n=50/50 follow-up: 9 months	coated Bx-VELOCITY versus Bx-VELOCITY	Stable or unstable AP, silent ischaemia	Parallel groups double-blind Canada
DECODE , 2005 *unpublished* [NCT00489164] n=54/29 follow-up: 1 year	CYPHER (Up to 3 stents per patient were allowed) versus Bx VELOCITY (Up to 3 stents per patient were allowed)	Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels	Parallel groups open US, Asia/Pacific
DESSERT , 2008 n=75/75 follow-up: 12 months	Cypher andCypher Select versus Sonic (Cordis)	de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >3 months	Parallel groups single-blind Italy
DIABETES , 2005 n=80/80 follow-up: 9 months	Cypher versus Bx Velocity/Sonic	de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm	Parallel groups open Spanish

continued...

Trial	Treatments	Patients	Trials design and methods
E-SIRIUS , 2003 [NCT00235144] n=175/177 follow-up: 9 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment	Parallel groups open Europe
GISSOC II , 2010 [NCT00220558] n=78/74 follow-up: 8 months	Sirolimus Eluting Stent versus Bare Metal Stent	patients with Chronic Total Occlusion older than 1 month, and successful recanalization	Parallel groups open Italy
Kochiadakis , 2007 n=38/43 follow-up: 4.8 months (mean)	sirolimus-eluting stents versus bare metal stent	one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm	Parallel groups open Greece
Ortolani et al , 2007 n=NA follow-up: 9 months	Cypher versus Vision	symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent	Parallel groups single-blind
Pache et al , 2005 n=250/250 follow-up: 12 months	Cypher versus BeStent 2	with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels	Parallel groups open Germany
Pasceri , 2003 *unpublished* n=NA follow-up: 12 months	-	-	Parallel groups
PRISON II , 2006 [NCT00258596] n=100/100 follow-up: 6 months	Cypher versus BxVelocity	Chronic total occlusion, positive exercise stress test	Parallel groups single-blind Belgium
RAVEL , 2002 [NCT00233805] n=120/118 follow-up: 12 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery	Parallel groups double-blind Global
SCANDSTENT , 2006 [NCT00151658] n=163/159 follow-up: 7 months	Cypher versus Sonic	Stable or unstable AP, recent AMI (non ST-elevation); with one or more de novo complex lesions in native coronary vessels (occluded, bifurcational, ostial or angulated)	Parallel groups open Denmark
SCORPIUS , 2007 [NCT00495898] n=98/102 follow-up: 12 months	Cypher versus Bx-Velocity	patients with diabetes and de novo coronary artery lesions	Parallel groups open Germany

continued...

Trial	Treatments	Patients	Trials design and methods
SES-SMART , 2004 n=129/128 follow-up: 8 months	Cypher versus Bx Sonic	Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test	Parallel groups single-blind Italian
SIRIUS , 2003 [NCT00232765] n=533/525 follow-up: 9 months	SES versus Bx Velocity	Stable or unstable AP, signs of myocardial ischaemia	Parallel groups double-blind United States
zotarolimus eluting stent vs bare-metal stent			
ENDEAVOR II , 2006 n=598/599 follow-up: 12 months	AVE Zotarolimus-Eluting Driver versus Driver	single de novo native coronary artery stenosis	Parallel groups double-blind worldwide
PCI with or without stent vs medical treatment			
TIME , 2001 n=NA follow-up:	coronary angiography and revascularisation versus optimised medical therapy	patients aged 75 years or older with chronic angina of at least Canadian Cardiac Society class II despite at least two antianginal drugs	Parallel groups open
AVERT , 1995 n=177/164 follow-up: 1.5y	angioplasty versus atorvastatin at 80 mg per day	Angina or asymptomatic, MI orunstable angina but not within 14 days,no triple vessel disease	Parallel groups open
Dakik , 1998 n=19/22 follow-up: 1y	PTCA versus intensive medical therapy	stable survivors of AMI	Parallel groups open
MASS II , 2007 n=205/203 follow-up: 5y	PCI versus medical therapy	patients with multivessel coronary artery disease with stable angina and preserved ventricular function	Parallel groups open
COURAGE , 2007 [NCT00007657] n=1149/1138 follow-up: median 4.6 y	PCI coupled with optimal medical therapy versus optimal medical therapy aloneitm	patients with stable coronary artery disease	Parallel groups open Canada, US
ALKK , 2003 n=149/151 follow-up: 4.7y	angioplasty versus medical therapy	patients with single vessel disease of the infarct vessel and no or minor angina pectoris in the subacute phase (1 to 6 weeks) after an acute myocardial infarction	Parallel groups open Germany
Hambrecht , 2004 n=50/51 follow-up: 1y	PCI versus 12 months of exercise training (20 minutes of bicycle ergometry per day)	male patients aged 70 years	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
Bech , 2001 n=90/91 follow-up: 2y	PTCA versus deferral of PTCA	patients with planned PTCA and no documented ischemia and with coronary pressurederived fractional flow reserve >0.75	Parallel groups open
ISCHEMIA *ongoing* n=NA follow-up:	invasive strategy, consisting of early routine cardiac catheterization followed by revascularization plus optimal medical therapy (OMT) and lifestyle changes versus conservative strategy of optimal medical therapy and lifestyle changes in which invasive procedures will be performed only after failure of OMT	patients with stable ischemic heart disease and moderate to severe ischemia	Parallel groups open-label
dexamethasone eluting stent vs bare-metal stent			
FEMH-93005 *ongoing* [NCT00190099] n=NA	-	-	
drug-eluting stents vs bare-metal stent			
ISAR-CABG *ongoing* [NCT00611910] n=NA follow-up:	DES versus BMS	Bypass Graft Lesions	open
crush stenting vs culotte stenting			
Nordic Bifurcation Stent Technique Study *ongoing* [NCT00292305] n=NA follow-up:	crush stenting versus culotte stenting	bifurcation lesions	
sirolimus eluting stent vs cutting ballon angioplasty			
FOCUS *ongoing* [NCT00485004] n=NA follow-up:	sirolimus-eluting implantation cypher versus cutting balloon angioplasty	focal in-stent restenosis after drug-eluting stent	
paclitaxel eluting stent vs CABG			
SYNTAX , 2009 [NCT00114972] n=903/897 follow-up: 1 year	paclitaxel (taxus Express SR) versus Coronary Artery Bypass Surgery (on- or off-pump bypass)	patients with previously untreated three-vessel or left main coronary artery disease (or both) (complex lesions)	Parallel groups open
PCI with drug-eluting stents vs CABG			
SYNTAX (diabetic) , 2010 [NCT00114972] n=NA follow-up: 1 year	paclitaxel-eluting stents versus surgical revascularization	sub group of diabetic patients with left main and/or 3-vessel disease	Parallel groups

continued...

Trial	Treatments	Patients	Trials design and methods
FREEDOM , 2012 [NCT00086450] n=953/947 follow-up: 3.8 yrs (median)	percutaneous coronary stenting versus CABG	patients with diabetes and multivessel coronary artery disease	Parallel groups open international
PCI withdrug-eluting stents vs CABG			
Hong , 2005 n=119/70 follow-up: 9 months	drug-eluting stents versus invasive direct coronary artery bypass (MIDCAB) surgery	proximal left anterior descending (LAD) coronary artery stenosis	Parallel groups open
VA CARDS *ongoing* [NCT00326196] n=NA follow-up:	percutaneous coronary stenting with drug eluding stents versus CABG	angiographically significant coronary artery disease in diabetes	Parallel groups open
stent vs CABG			
ARTS , 2001 n=600/605 follow-up: 1 year	Palmaz-Schatz Crown/Cross flex (Cordis) versus Conventional CABG	Multi vessel disease with 2 or more de novo lesion in different major arteries Total occlusion <1month	parallel group open International
CARDia (PCI) , 2008 [ISRCTN19872154] n=256/254 follow-up: 1 y	PCI plus stenting (and routine abciximab) versus CABG	Patients with diabetes and symptomatic multivessel coronary artery disease or complex single-vessel disease.	Parallel groups open UK, Ireland
ERACI II , 2003 n=225/225 follow-up: 30d, 1year	Gianturco Robin II (Cook) Primary device versus Conventional CABG	multi vessel disease Angina CSS III-IV; no angina but large area of heart at risk; unstable =1 vessel to be treated Lesion>3.0mm	parallel group open Argentinad
LEMANS , 2002 [NCT00375063] n=52/53 follow-up: 1y	unprotected left main stenting versus coronary artery bypass grafting	patients with unprotected left main coronary artery stenosis	Parallel groups open Poland
MASS II , 2007 n=205/203 follow-up: 5y (1y)	PCI (73% stent) versus CABG	patients with multivessel coronary artery disease with stable angina and preserved ventricular function	Parallel groups open South America
Myoprotect , 2004 n=23/21 follow-up: 1 year	percutaneous transluminal coronary angioplasty/stent versus CABG	patients with symptomatic main-stem and main-stem-equivalent lesions with substantially increased risk for bypass surgery	Parallel groups open Europe
SOS , 2002 [NCT00475449] n=488/500 follow-up: 3 years	Stent versus CABG	multiple vessel disease Symptomatic 1 or more vessel suitable for stenting	parallel group open Canada, United Kingdom, Europe
stent vs E-ACAB			

continued...

Trial	Treatments	Patients	Trials design and methods
Cisowski n=50/50 follow-up: 2 years	Tristar, Tera, Penta (Guidant) (Cordis) versus endoscopic atraumatic coronary artery bypass grafting	single vessel disease ACC/AHA A or B lesion in proximal LAD Angina CCS II or higher Lesion diameter 3 mm orgreater/length 20mm or greater	parallel group open Poland
zotarolimus eluting stent vs everolimus eluting stent			
RESOLUTE All comers , 2010 [NCT00617084.)] n=1140/1152 follow-up: 12 months (5y)	zotarolimus-eluting stent versus everolimus-eluting stent (Xience)	adult patients with chronic, stable coronary artery disease or acute coronary syndromes, including myocardial infarction with or without ST-segment elevation	Parallel groups open
stent vs MIDCAB			
Diegeler , 2002 n=110/110 follow-up: 5 years	Various stents versus minimally invasive direct coronary artery bypass (off-pump proceedure)	single vessel disease Lesion =75% stenosis in proximal LAD or between origin of left circumflex and 1st septal branch	parallel group open Germany
Drenth , 2002 n=51/51 follow-up: 6 months, 3 years	Stent type not reported versus minimally invasive direct coronary artery bypass (off-pump proceedure	single vessel disease Angina II Lesion (Grade B2 or C) of proximal LAD Suitable for CABG or stenting	parallel group open Netherlands
Grip , 2001 n=28/25 follow-up:	Stent type not reported versus minimally invasive direct coronary artery bypass (off-pump proceedure)	single vessel disease engaging LAD Stable or unstable angina	parallel group open Sweden
Kim , 2005 n=50/50 follow-up: 2 years	Stent versus MIDCAB using ministernotomy	patients with isolated proximal left anterior descending artery disease	Parallel groups open Korea
SIMA , 2000 n=62/59 follow-up: 2.4 years	Any CE marked, but Palmaz-Schatz recommended versus Conventional CABG or minimally invasive direct coronary artery bypass (off-pump proceedure) (10% of surgical procedures	single vessel disease Symptomatic or silent ischaemia 1 LAD lesion Ejection fraction >45% Vessel >3.0mm	parallel group open Europe
stent vs OPCAB			
OCTOSTENT , 2003 [NCT00975858] n=138/142 follow-up: 1 year	Stent type not reported versus off-pump coronary artery bypass	multi or single vessel disease Moderate LV function CABG or stenting to be considered feasible	Parallel groups open Europe
CoStar stent vs paclitaxel eluting stent			

continued...

Trial	Treatments	Patients	Trials design and methods
Costar II , 2008 [NCT00165035] n=989/686 follow-up: 8 months (1 year)	CoStar stent (Conor MedSystems) PES versus Taxus (Boston Scientific) PES	patient undergoing percutaneous coronary intervention for a single lesion per vessel in up to three native epicardial vessels	Parallel groups single-blind US, Germany, Belgium, and New Zealand
everolimus eluting stent vs paclitaxel eluting stent			
COMPARE , 2009 [NCT01016041] n=897/903 follow-up: 1 y (2y)	polymer based, everolimus-eluting stent (Xience V) versus polymer-based, paclitaxel-eluting stent (Taxus Liberte)	unselected patients	Parallel groups open the Netherlands
SPIRIT II , 2006 *unpublished* [NCT00180310] n=223/77 follow-up: 6 months	everolimus eluting stent, XIENCE V versus placitaxel eluting stent, TAXUS EXPRESS2	De novo lesions (maximim two)	Parallel groups single-blind (patient)
SPIRIT III , 2008 [NCT00180479] n=669/333 follow-up: 12 months	everolimus-eluting stent, XIENCE V versus paclitaxel-eluting stent, Taxus	lesions 28 mm or less in length and with reference vessel diameter between 2.5 and 3.75 m	Parallel groups single-blind US
SPIRIT IV , 2010 [NCT00307047] n=2458/1229 follow-up: 1 y (2y)	XIENCE V Everolimus Eluting Coronary Stent System versus TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System (TAXUS).	patients with de novo native coronary artery lesions and reference vessel diameters between 2.5 mm to 4.25 mm and lesion lengths <= 28 mm	Parallel groups 270 days (5 years) USA
sirolimus eluting stent vs paclitaxel eluting stent			
BASKET (vs paclitaxel) , 2005 n=264/281 follow-up: 6 months	Cypher versus Taxus	Unselected patients; de-novo lesions	Parallel groups open Switzerland,
Cervinka , 2006 n=37/33 follow-up: 6 months	sirolimus-eluting stent versus paclitaxel-eluting stent	Complex lesionsand patients. Signs and/or symptoms myocardial ischaemia, including AMI	Parallel groups open
CORPAL , 2005 *unpublished* n=331/321 follow-up:	sirolimus versus paclitaxel	Documented myocardial ischaemia, no AMI	Parallel groups open Spain
Di Lorenzo et al. , 2005 *unpublished* n=90/90 follow-up:	sirolimus versus paclitaxel	ST-segment elevation myocardial infarction	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
Han , 2006 n=210/206 follow-up: 19.5 months (mean)	Cypher versus Taxus	Multivessel disease. Stable or unstable AP, no AMI	Parallel groups open China
ISAR-DESIRE (SES vs PES) , 2005 n=100/100 follow-up: 1y	Cypher versus Taxus	In-stent restenosis. AP and/or positive test, previously stented, no AMI	Parallel groups open germany
ISAR-DIABETES , 2005 n=125/125 follow-up: 9 months	Taxus versus Cypher	Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel	Parallel groups open Germany
ISAR-LEFT-MAIN , 2009 [NCT00133237] n=302/305 follow-up: 1 year	Paclitaxel-eluting stent versus Sirolimus-eluting stent	Unprotected Left Main Coronary Artery Disease	Parallel groups open
ISAR-SMART 3 , 2006 [NCT00146575] n=180/180 follow-up:	Taxus versus Cypher	Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMI	Parallel groups NA Germany
ISAR-TEST-1 , 2006 [NCT00140530] n=225/225 follow-up: 9 months	rapamycin-eluting stent Yukon versus Taxus	stable or unstable anginaor a positive stress test, stable or unstable anginaor a positive stress test	Parallel groups open Germany
Kim , 2008 n=85/84 follow-up: 6 months	Cypher versus Taxus	Korean diabetic patients with high-grade de novo coronary lesions (stenosis of>70 percent of the luminal diameter) requiring <3 stents	Parallel groups open Korea
LONG DES II , 2006 n=250/250 follow-up: 9 months	SES versus PES	Long lesions. AP or positive stress, no AMI	Parallel groups single-blind Korea
Petronio et al , 2007 n=50/50 follow-up: 9 months	Cypher versus Taxus	Complex lesions. Stable AP or documented ischaemia, no AMI	Parallel groups open Italy
REALITY , 2006 [NCT00235092] n=701/685 follow-up: 12 months	Cypher versus Taxus	Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries	Parallel groups open Europe, Latin America, and Asiam

continued...

Trial	Treatments	Patients	Trials design and methods
SIRTAX (Windecker) , 2005 n=503/509 follow-up: 9 mo (5y)	sirolimus-eluting stents (Cypher) versus paclitaxel-eluting stents (Taxus)	Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation	Parallel groups single-blind Switzerland
TAXi , 2005 n=102/100 follow-up: 6 months	Cypher versus Taxus	Unselected patients	Parallel groups open Switzerland.
Tomai , 2008 n=60/60 follow-up: 8 months	sirolimus-eluting stent versus paclitaxel-eluting stent	diabetic patient with multiple de novo coronary artery lesions	Cross over NA Italy
Zhang (SES vs PES) , 2006 n=246/203 follow-up: 1y	Cypher versus Taxus	Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions	Parallel groups open China
DES-ISR *ongoing* [NCT00485030] n=NA follow-up:	Cypher versus Taxus	patients Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation	
Lipsia-Yukon-DM *ongoing* [NCT00368953] n=NA follow-up: 9 months	Yukon Choice stent system versus Taxus Libert stent system	Patients With Diabetes Mellitus	
zotarolimus eluting stent vs paclitaxel eluting stent			
ENDEAVOR IV , 2009 *unpublished* [NCT00217269] n=773/775 follow-up: mean 36 mo	zotarolimus-eluting stent (Endeavor) versus paclitaxel-eluting stent (Taxus)	single de novo lesions in native coronary arteries with a reference vessel diameter of 2.5-3.5 mm	Parallel groups open US
ZoMaxx phase 2 *ongoing* [NCT00140101] n=NA follow-up:	ZoMaxx drug-eluting stent versus TAXUS Express2	de Novo Coronary Artery Lesions	
biolimus eluting stent vs sirolimus eluting stent			
LEADERS , 2008 [NCT00389220] n=857/850 follow-up: 9 months	BioMatrix III (biolimus-eluting stent withbiodegradable polymer) versus Cypher SELECT (sirolimus-eluting stent with durable polymer)	patients aged 18 years or older with chronic stable coronary artery disease or acute coronary syndromes	Parallel groups open assessor-blind Europe
everolimus eluting stent vs sirolimus eluting stent			

continued...

Trial	Treatments	Patients	Trials design and methods
ISAR-TEST 4 (EES vs SES) n=652/652 follow-up: 2 years	everolimus-eluting stent versus sirolimus-eluting stent	patients with de novo coronary artery stenosis >50% and symptoms or objective evidence of ischemia	Parallel groups
SORT OUT IV , 2012 [NCT00552877] n=1390/1384 follow-up: 9 months (3 years)	everolimus-eluting stents versus sirolimus-eluting stents	unselected patients with coronary artery disease	Parallel groups open Denmark
drug-eluting stents vs CABG			
Leipzig *ongoing* [NCT00176397] n=NA follow-up:	PCI With DES versus CABG	left main coronary stenosis	
sirolimus eluting stent vs CABG			
MIDCAB Versus DES in Proximal LAD Lesions *ongoing* [NCT00299429] n=NA follow-up:	sirolimus-coated stent versus minimally invasive bypass surgery	patients with isolated proximal left anterior descending coronary arteries	
paclitaxel eluting stent vs medical treatment			
VELETI *ongoing* [NCT00289835] n=NA follow-up:	TAXUS versus standard medical treatment	Moderate Vein Graft Lesions	
paclitaxel eluting stent vs paclitaxel eluting stent			
PERSEUS Workhorse , 2010 *ongoing* [NCT00484315] n=NA follow-up:	platinum-chromium alloy, paclitaxel-eluting stent TAXUS Element versus paclitaxel-eluting stent TAXUS Express 2	De Novo Coronary Artery Lesions; stent patients with lesions <28 mm in length in coronary vessels between 2.75 mm and 4.0 mm in diameter	

More details and results :

- myocardial revascularization for stable angina in all type of patient at http://www.trialresultscenter.org/go-Q25
- myocardial revascularization for stable angina in single vessel disease at http://www.trialresultscenter.org/go-Q27
- myocardial revascularization for stable angina in multivessels disease at http://www.trialresultscenter.org/go-Q28
- myocardial revascularization for stable angina in diabetic patients at http://www.trialresultscenter.org/go-Q29

References

Lincoff (EPISTENT), 1999:

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999 Jul 29;341:319-27 [10423466]

—Z Lancet 1998 Jul 11;352:87-92 [9672272]

Hoher, 1999:

Hoher M, Wohrle J, Grebe OC, Kochs M, Osterhues HH, Hombach V, Buchwald AB A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol 1999 Sep;34:722-9 [10483953]

Serruys Benestent, 1994:

Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95 [8041413]

Macaya C, Serruys PW, Ruygrok P, Suryapranata H, Mast G, Klugmann S, Urban P, den Heijer P, Koch K, Simon R, Morice MC, Crean P, Bonnier H, Wijns W, Danchin N, Bourdonnec C, Morel MA Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol 1996;27:255-61 [8557891]

Fischman STRESS, 1994:

Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501 [8041414]

Eeckout, 1996:

Eeckhout E, Stauffer JC, Vogt P, Debbas N, Kappenberger L, Goy JJ Comparison of elective Wiktor stent placement with conventional balloon angioplasty for new-onset lesions of the right coronary artery. Am Heart J 1996 Aug;132:263-8 [8701885]

Sirnes, 1996:

Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus J Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol 1996 Nov 15;28:1444-51 [8917256]

Versaci , 1997:

Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997;336:817-22 [9062089]

Savage, 1998:

Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg S Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997 Sep 11;337:740-7 [9287229]

Erbel, 1998:

Erbel R, Haude M, Hopp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998 Dec 3;339:1672-8 [9834304]

Rubartelli, 1998:

Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini G Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. J Am Coll Cardiol 1998 Jul;32:90-6 [9669254]

Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini G Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. J Am Coll Cardiol 1998 Jul;32:90-6 [9669254]

Hancock, 1998:

Hancock J, Thomas MR, Holmberg S, Wainwright RJ, Jewitt DE Randomised trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries. Heart 1998 Jan;79:18-23 [9505913]

Serruys Benestent 2, 1998:

Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) Lancet 1998;352:673-81 [9728982]

Rodriguez, 1998:
Rodriguez A, Ayala F, Bernardi V, Santaera O, Marchand E, Pardinas C, Mauvecin C, Vogel D, Harrell LC, Palacios IF Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results. J Am Coll Cardiol 1998 Nov;32:1351-7 [9809947]
Sievert, 1999:
Sievert H, Rohde S, Utech A, Schulze R, Scherer D, Merle H, Ensslen R, Schrader R, Spies H, Fach A Stent or angioplasty after recanalization of chronic coronary occlusions? (The SARECCO Trial). Am J Cardiol 1999 Aug 15;84:386-90 [10468073]
Betriu, 1999:
Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delcan JL, Garcia E, Calabuig J Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999 Nov 1;34:1498-506 [10551699]
Buller, 1999:
Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, Anderson TJ, Knudtson ML, Marquis JF, Suzuki T, Cohen EA, Fox RS, Teo KK Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999 Jul 20;100:236-42 [10411846]
Serruys, 2000:
Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, Vrints C, Probst P, Seabra-Gomes R, Simpson I, Voudris V, Gurne O, Pijls N, Belardi J, van Es GA, Boersma E, Morel MA, van Hout B Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. Circulation 2000 Dec 12;102:2930-7 [11113042]
Di Marlo, 2000:
Di Mario C, Moses JW, Anderson TJ, Bonan R, Muramatsu T, Jain AC, Suarez de Lezo J, Cho SY, Kern M, Meredith IT, Cohen D, Moussa I, Colombo A Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint STenting INternational Investigation). Circulation 2000 Dec 12;102:2938-44 [11113043]
Kastrati, 2000:
Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann FJ A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000 Nov 21;102:2593-8 [11085962]
Witkowski, 2000:
Witkowski A, Ruzyllo W, Gil R, Gorecka B, Purzycki Z, Kosmider M, Polonski L, Lekston A, Gasior M, Zmudka K, Pieniazek P, Buszman P, Drzewiecki J, Ciecwierz D, Sadowski Z A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators. Am Heart J 2000 Aug;140:264-71 [10925341]
Lafont, 2000:
Lafont A, Dubois-Rande JL, Steg PG, Dupouy P, Carrie D, Coste P, Furber A, Beygui F, Feldman LJ, Rahal S, Tron C, Hamon M, Grollier G, Commeau P, Richard P, Colin P, Bauters C, Karrillon G, Ledru F, Citron B, Marie FN, Kern M The French Randomized Optimal Stenting Trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. F.R.O.S.T. Study Group. J Am Coll Cardiol 2000 Aug;36:404-9 [10933349]
Fluck, 2000:
Fluck DS, Chenu P, Mills P, Davies A, Street J, Paul E, Balcon R, Layton CA Is provisional stenting the effective option? The WIDEST study (Wiktor stent in de novo stenosis). Widest Trial Investigators' Group. Heart 2000 Nov;84:522-8 [11040014]
Dangas, 2000:
Dangas G, Ambrose JA, Rehmann D, Marmur JD, Sharma SK, Hemdal-Monsen C, Sanborn TA, Fischman DL Balloon optimization versus stent study (BOSS): provisional stenting and early recoil after balloon angioplasty. Am J Cardiol 2000 Apr 15;85:957-61 [10760334]
Weaver, 2000:
Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PP, Henry T, D'Haem C, Clark VL, Martin JS, Cohen DJ, Neil N, Every NR Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet 2000 Jun 24;355:2199-203 [10881893]
Lotan, 2000:
Lotan C, Rozenman Y, Hendler A, Turgeman Y, Ayzenberg O, Beyar R, Krakover R, Rosenfeld T, Gotsman MS Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. Eur Heart J 2000 Dec;21:1960-6 [11071802]

Park, 2000:

Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY, Park SJ Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 2000 Nov;21:1785-9 [11052843]

Koning, 2001:

Koning R, Eltchaninoff H, Commeau P, Khalife K, Gilard M, Lipiecki J, Coste P, Bedossa M, Lefevre T, Brunel P, Morice MC, Maillard L, Guyon P, Puel J, Cribier A Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. Circulation 2001 Oct 2;104:1604-8 [11581136]

Doucet, 2001:

Doucet S, Schalij MJ, Vrolix MC, Hilton D, Chenu P, de Bruyne B, Udayachalerm W, Seth A, Bilodeau L, Reiber JH, Harel F, Lesperance J Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation 2001 Oct 23;104:2029-33 [11673341]

Moer, 2001:

Moer R, Myreng Y, Molstad P, Albertsson P, Gunnes P, Lindvall B, Wiseth R, Ytre-Arne K, Kjekshus J, Golf S Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol 2001 Nov 15;38:1598-603 [11704369]

ACTION, 2004:

Serruys PW, Veldhof S, Stuteville M, et al Actinomycin-elutingstent improves outcome by reducing neointimal hyperplasia Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002

Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schmig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH, Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel K, Johnson R, Coleman L, Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 2004 Oct 6;44:1363-7 [15464314]

FUTURE I, 2004:

Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71 [15123533]

FUTURE II, 2006:

unpublished

Grube E, Lansky A, Mehran R, Fitzgerald P, Ho Multicenter evaluation of the bioabsorbable polymer-basedeverolimus-eluting stent: FUTURE-2 trial Transcatheter-Cardiovascular Therapeutic Annual Meeting, September, 2003

Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Mller R, Strger H, Hauptmann KE, Grube E Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006 Aug 15;98:464-9 [16893698]

Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004 May 11;109:2168-71 [15123533]

SPIRIT I, 2005:

Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005 May;1:58-65 [19758878]

Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention 2005 Nov;1:266-72 [19758915]

Tsuchida K, Garca-Garca HM, Ong AT, Valgimigli M, Aoki J, Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PW Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv 2006 Feb;67:188-97 [16400664]

SCORE, 2004:

Stone GW. Adverse outcomes from a taxane-loaded polymericsleeved stent: final results from the SCORE Tria AmericanCollege of Cardiology Scientific Session, March, 2002

Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell ME High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004 Oct 6;44:1368-72 [15464315]

TAXUS I, 2003:

Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42 [12515740]

Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003 Jan 7;107:38-42 [12515740]

TAXUS II, 2003:

Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94 [12900339]

Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, Dudek D, Baim DS Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009 Oct 13;120:1498-504 [19786634]

TAXUS IV, 2004:

Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31 [14724301]

Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents 5-Year Final Results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009 Dec;2:1248-59 [20129552] 10.1016/j.jcin.2009.10.003

Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009;2:1248-59 [20129552] 10.1016/j.jcin.2009.10.003

TAXUS V (all patients), 2005:

Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23 [16160130]

TAXUS VI, 2005:

Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13 [16286586]

Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Buellesfeld L, Koglin J, Russell ME TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007;28:2578-82 [17938126]

Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Joshi A, Mascioli S TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention 2009;4:572-7 [19378676]

BASKET-SAVAGE, 0:

ongoing trial NCT00595647

ASPECT, 2003:

Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45 [12700373]

DELIVER, 2004:

ONeill WW, Knopf W, Lansky A, Fitzgerald P, Mahaffey K. Randomized comparison of paclitaxel-coated versus metallic stentsfor treatment of coronary lesions American College of CardiologyScientific Session, March, 2003

Knopf W, ONeill WW, Lansky A, Fitzgerald P, Mahaffey KE Randomized comparison of paclitaxel-coated versus metallicstents for treatment of coronary lesions TranscatheterCardiovascular Therapeutics Annual Meeting, September, 2003

Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WW Non-polymer-based paclitaxel-coated coronary stents for the treatment

of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004 Apr 27;109:1948-54 [15078794]

ELUTES, 2004:

Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93 [14744971]

PATENCY, 2002:

unpublished

Heldman A, Farhat N, Fry E, et al.b Paclitaxel-eluting stent for cytostatic prevention of restenosis: the PATENCY Study Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002

C-SIRIUS, 2004:

Schampaert E, Cohen EA, Schlter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5 [15028375]

DECODE, 2005:

unpublished

Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M. Outcomesin diabetic patients with multivessel disease and long lesions: resultsfrom the DECODE study Am J Cardiol 2005; 96 (suppl 7A): 31H

DESSERT, 2008:

Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P, Zoccai GB Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 2008;101:1560-6 [18489933]

DIABETES, 2005:

Sabat M, Jimnez-Quevedo P, Angiolillo DJ, Gmez-Hospital JA, Alfonso F, Hernndez-Antoln R, Goicolea J, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83 [16203930]

Jimnez-Quevedo P, Sabat M, Angiolillo DJ, Alfonso F, Hernndez-Antoln R, SanMartn M, Gmez-Hospital JA, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007;28:1946-52 [17562666]

Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L Am J Cardiol 2009 Feb 1;103:345-9 [19166687]

E-SIRIUS, 2003:

Schofer J, Schlter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9 [14550694]

GISSOC II, 2010:

Rubartelli P, Petronio AS, Guiducci V, Sganzerla P, Bolognese L, Galli M, Sheiban I, Chirillo F, Ramondo A, Bellotti S Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. Eur Heart J 2010;: [20566487] 10.1093/eurheartj/ehq199

Kochiadakis, 2007:

Kochiadakis GE, Marketou ME, Arfanakis DA, Sfiridaki K, Skalidis EI, Igoumenidis NE, Hamilos MI, Kolyvaki S, Chlouverakis G, Kantidaki E, Castanas E, Vardas PE, Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. Atherosclerosis 2007;194:433-8. [16997310] 10.1016/j.atherosclerosis.2006.08.029

Ortolani et al, 2007:

Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F, Silenzi S, Cooke RM, Reggiani ML, Branzi A Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv 2007;69:790-8 [17290437]

Pache et al, 2005:

Pache J, Dibra A, Mehilli J, Dirschinger J, Schmig A, Kastrati A Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8 [15737962]

Pasceri, 2003:
unpublished
Pasceri V, Granatelli A, Pristipino C, et al. A randomized trial of arapamycin-eluting stent in acute myocardial infarction: preliminaryresults TCT 2003. Am J Cardiol 2003;92(Suppl 6A):1L.
PRISON II, 2006:
Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006;114:921-8 [16908768]
RAVEL, 2002:
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnr F, Falotico R A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80 [12050336]
Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007 Oct 2;50:1299-304 [17903626]
SCANDSTENT, 2006:
Kelbaek H, Thuesen L, Helqvist S, Klvgaard L, Jrgensen E, Aljabbari S, Saunamki K, Krusell LR, Jensen GV, Btker HE, Lassen JF, Andersen HR, Thayssen P, Galle A, van Weert A The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006;47:449-55 [16412876]
Kelbaek H, Klvgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrm T, Btker HE, Jrgensen E, Saunamki K, Aljabbari S, Thayssen P, Galle A, Jensen GV, Thuesen L Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J Am Coll Cardiol 2008 May 27;51:2011-6 [18498953]
SCORPIUS, 2007:
Baumgart D. One year results of the SCORPIUS-Trial - a Germanmulticenter investigation on the eff ectiveness of sirolimus-elutingstents in diabetic patients Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics. Washington, DC;Oct 2227, 2006. Abstract 288.
Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Vlker W, Pfannebecker T, Stoll HP, Nickenig G One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007 Oct 23;50:1627-34 [17950142]
SES-SMART, 2004:
Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34 [15585732]
SIRIUS, 2003:
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23 [14523139]
Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MB Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Am J Cardiol 2007 Apr 15;99:1044-50 [17437725]
Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-40 [14769686]
Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009 Apr 28;53:1488-97 [19389558] 10.1016/j.jacc.2009.01.050
Novack V, Nguyen MC, Rooney M, Chacko R, Novack L, Pencina M, Apruzzese P, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DE Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. Am J Cardiol 2010 Sep 15;106:774-9 [20816116] 10.1016/j.amjcard.2010.04.039
ENDEAVOR II, 2006:
Gruberg L. ENDEAVOR II. A randomized comparison of the Endeavor ABT-578 drug-eluting stent with a bare metal stent for coronary revascularization,powerpo http://www.medscape.com/viewarticle/501475

Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006 Aug 22;114:798-806 [16908773]

Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol 2007 Feb;55:1-18 [17287679]

Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, Cutlip D, Popma JJ, Zimetbaum P, Fajadet J, Kuntz RE, Wijns W, Fitzgerald PJ Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007 Sep 1;100:818-23 [17719326]

Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, Kong DF, Anstrom KJ Long-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009 Dec;2:1178-87 [20129543] 10.1016/j.jcin.2009.10.011

TIME, 2001:

Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001;358:951-7 [11583747]

Masson C, Pruvo JP, Meder JF, Cordonnier C, Touz E, De La Sayette V, Giroud M, Mas JL, Leys D Spinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. J Neurol Neurosurg Psychiatry 2004;75:1431-5 [15377691]

Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, Eeckhout E, Erne P, Estlinbaum W, Kuster G, Moccetti T, Naegeli B, Rickenbacher P Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289:1117-23 [12622581]

AVERT, 1995:

Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators N Engl J Med 1999;341:70-6 [10395630]

Dakik, 1998:

Dakik HA, Kleiman NS, Farmer JA, He ZX, Wendt JA, Pratt CM, Verani MS, Mahmarian JJ Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study Circulation 1998;98:2017-23 [9808599]

MASS II, 2007:

Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease Circulation 2007;115:1082-9 [17339566] 10.1161/CIRCULATIONAHA.106.625475

Hueb W, Soares PR, Gersh BJ, Csar LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JA The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004;43:1743-51 [15145093]

Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122:949-57 [20733102] 10.1161/CIRCULATIONAHA.109.911669

COURAGE, 2007:

Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 Apr 12;356:1503-16 [17387127]

ALKK, 2003:

Zeymer U, Uebis R, Vogt A, Glunz HG, Vhringer HF, Harmjanz D, Neuhaus KL Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausrzte Circulation 2003;108:1324-8 [12939210] 10.1161/01.CIR.0000087605.09362.0E

Hambrecht, 2004:

Hambrecht R, Walther C, Mbius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler G Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial Circulation 2004;109:1371-8 [15007010] 10.1161/01.CIR.0000121360.31954.1F

Bech, 2001:

Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial Circulation 2001;103:2928-34 [11413082]

ISCHEMIA, :

ongoing trial

FEMH-93005, 0:

ongoing trial NCT00190099

ISAR-CABG, 0:

ongoing trial NCT00611910

Nordic Bifurcation Stent Technique Study, 0:

ongoing trial NCT00292305

FOCUS, 0:

ongoing trial NCT00485004

SYNTAX, 2009:

Lee TH, Hillis LD, Nabel EG CABG vs. stenting–clinical implications of the SYNTAX trial. N Engl J Med 2009 Feb 19;360:e10 [19228613] 10.1056/NEJMp0900462

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Sthle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009 Mar 5;360:961-72 [19228612] 10.1056/NEJMoa0804626

Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010;55:1067-75 [20079596] 10.1016/j.jacc.2009.09.057

SYNTAX (diabetic), 2010:

Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010;55:1067-75 [20079596]

FREEDOM, 2012:

Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov Strategies for Multivessel Revascularization in Patients with Diabetes. N Engl J Med 2012 Nov 4;: [23121323] 10.1056/NEJMoa1211585

Hong, 2005:

Hong SJ, Lim DS, Seo HS, Kim YH, Shim WJ, Park CG, Oh DJ, Ro YM Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. Catheter Cardiovasc Interv 2005;64:75-81 [15619278]

VA CARDS, 0:

ongoing trial NCT00326196

ARTS, 2001:

Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533-8 [11479249]

de Feyter PJ, Serruys PW, Unger F, Beyar R, de Valk V, Milo S, Simon R, Regensburger D, Crean PA, McGovern E, van den Heuvel P, van Cauwelaert C, Penn I, Tyers GF, Lindeboom W Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina. Circulation 2002;105:2367-72 [12021222]

Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, Lindeboom W, Backx B Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114-20 [14993134]

Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schnberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24 [11297702]

Unger F, Serruys PW, Yacoub MH, Ilsley C, Paulsen PK, Nielsen TT, Eysmann L, Kiemeneij F Revascularization in multivessel disease: comparison between two-year outcomes of coronary bypass surgery and stenting. J Thorac Cardiovasc Surg 2003;125:809-20 [12698143]

CARDia (PCI), 2008:

Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010 Feb 2;55:432-40 [20117456] 10.1016/j.jacc.2009.10.014

ERACI II, 2003:

Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, Vogel D, Grinfeld R, Delacasa A, Garrido M, Oliveri R, Mele E, Palacios I, O'Neill W Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001;37:51-8 [11153772]

Rodriguez A, Rodrguez Alemparte M, Baldi J, Navia J, Delacasa A, Vogel D, Oliveri R, Fernndez Pereira C, Bernardi V, O'Neill W, Palacios IF Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. Heart 2003;89:184-8 [12527674]

LEMANS, 2002:

Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, Bialkowska B, Dudek D, Gruszka A, Zurakowski A, Milewski K, Wilczynski M, Rzeszutko L, Buszman P, Szymszal J, Martin JL, Tendera M Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 2008;51:538-45 [18237682]

MASS II, 2007:

Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007 Mar 6;115:1082-9 [17339566]

Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122:949-57 [20733102] 10.1161/CIRCULATIONAHA.109.911669

Myoprotect, 2004:

Pohl T, Giehrl W, Reichart B, Kupatt C, Raake P, Paul S, Reichenspurner H, Steinbeck G, Boekstegers P Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter Cardiovasc Interv 2004;62:323-30 [15224298] 10.1002/ccd.20060

SOS, 2002:

Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002;360:965-70 [12383664]

Stables RH Design of the 'Stent or Surgery' trial (SoS): a randomized controlled trial to compare coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multi-vessel coronary artery disease. Semin Interv Cardiol 1999;4:201-7 [10738353]

Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, Weintraub WS Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation 2003;108:1694-700 [12975252]

Zhang Z, Weintraub WS, Mahoney EM, Spertus JA, Booth J, Nugara F, Stables RH, Vaccarino V Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). Am J Cardiol 2004;93:404-9 [14969611]

Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, Stables RH Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008;118:381-8 [18606919]

Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, Stables RH Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008 Jul 22;118:381-8 [18606919]

Cisowski, 0:

RESOLUTE All comers, 2010:

Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Dimario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. N Engl J Med 2010 Jun 16;: [20554978] 10.1056/NEJMoa1004130

Silber S, Windecker S, Vranckx P, Serruys PW Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011 Apr 1;: [21459430] 10.1016/S0140-6736(11)60395-4

Diegeler, 2002:

Diegeler A, Thiele H, Falk V, Hambrecht R, Spyrantis N, Sick P, Diederich KW, Mohr FW, Schuler G Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med 2002;347:561-6 [12192015]

Diegeler A, Spyrantis N, Matin M, Falk V, Hambrecht R, Autschbach R, Mohr FW, Schuler G The revival of surgical treatment for isolated proximal high grade LAD lesions by minimally invasive coronary artery bypass grafting. Eur J Cardiothorac Surg 2000;17:501-4 [10814909]

Drenth, 2002:

Drenth DJ, Veeger NJ, Grandjean JG, Mariani MA, van Boven AJ, Boonstra PW Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? Eur J Cardiothorac Surg 2004;25:567-71 [15037273]

Drenth DJ, Veeger NJ, Winter JB, Grandjean JG, Mariani MA, Boven van AJ, Boonstra PW A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. J Am Coll Cardiol 2002;40:1955-60 [12475455]

Drenth DJ, Winter JB, Veeger NJ, Monnink SH, van Boven AJ, Grandjean JG, Mariani MA, Boonstra PW Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months' angiographic and clinical follow-up of a prospective randomized study. J Thorac Cardiovasc Surg 2002;124:130-5 [12091818]

Grip, 2001:

Grip L, Wahrborg P, Odell A, Albertsson P, Berglin E, Brandrup- Coronary artery bypass beating heart surgery with LIMA graft, versus coronary angioplasty with stent for patients with single left anterior descending artery - a pilot study European Heart Journal 2001;22 (Suppl):597

Kim, 2005:

Kim JW, Lim DS, Sun K, Shim WJ, Rho YM Stenting or MIDCAB using ministernotomy for revascularization of proximal left anterior descending artery? Int J Cardiol 2005;99:437-41 [15771925]

SIMA, 2000:

Goy JJ, Kaufmann U, Goy-Eggenberger D, Garachemani A, Hurni M, Carrel T, Gaspardone A, Burnand B, Meier B, Versaci F, Tomai F, Bertel O, Pieper M, de Benedictis M, Eeckhout E A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc 2000;75:1116-23 [11075740]

OCTOSTENT, 2003:

Eefting F, Nathoe H, van Dijk D, Jansen E, Lahpor J, Stella P, Suyker W, Diephuis J, Suryapranata H, Ernst S, Borst C, Buskens E, Grobbee D, de Jaegere P Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation 2003;108:2870-6 [14656913]

van Dijk D, Nierich AP, Eefting FD, Buskens E, Nathoe HM, Jansen EW, Borst C, Knape JT, Brede JJ, Robles de Medina EO, Grobbee DE, Diephuis JC, de Jaegere PP The Octopus Study: rationale and design of two randomized trials on medical effectiveness, safety, and cost-effectiveness of bypass surgery on the beating heart. Control Clin Trials 2000;21:595-609 [11146152]

Costar II, 2008:

Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008 Apr 22;51:1543-52 [18420096]

Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. J Invasive Cardiol 2008;20:335-41 [18599890]

COMPARE, 2009:

Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010 Jan 16;375:201-9 [20060578] 10.1016/S0140-6736(09)62127-9

Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice The COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE? stent in all-comers: a randomized open label trial) Trial. J Am Coll Cardiol 2011 Apr 15;: [21514083] 10.1016/j.jacc.2011.02.023

SPIRIT II, 2006:

unpublished

Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hbert K, Sudhir K, Boland J, Huber K, Garcia E, Te Riele JA 3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions The SPIRIT II Trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009 Dec;2:1190-8 [20129545] 10.1016/j.jcin.2009.10.002

Onuma Y, Tanimoto S, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carri D, Thuesen L, Dorange C, Miquel-Hebert K, Veldhof S, Serruys PW Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. Catheter Cardiovasc Interv 2010;76:634-42 [20690152] 10.1002/ccd.22541

SPIRIT III, 2008:

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ, , Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13. [18430909] 10.1001/jama.299.16.1903

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL Circulation 2009;119:680-6 [19171853]

Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention 2010;6:437-46 [20884430] 10.4244/EIJ30V6I4A75

SPIRIT IV, 2010:

Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009;158:520-526.e2 [19781409]

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010 May 6;362:1663-74 [20445180] 10.1056/NEJMoa0910496

Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010;56:2084-9 [21144968] 10.1016/j.jacc.2010.10.006

Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents 2-Year Follow-Up From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV Trial. J Am Coll Cardiol 2011 Apr 15;: [21514084] 10.1016/j.jacc.2011.02.022

BASKET (vs paclitaxel), 2005:

Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitts Trial (BASKET). Lancet 2005;366:921-9 [16154019]

Cervinka, 2006:

Cervinka P, Costa MA, Angiolillo DJ, Spacek R, Bystron M, Kvasnk M, Veselka J, Nanda H, Futamatsu H, Futamatsu K "Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study". Catheter Cardiovasc Interv 2006;67:846-51 [16683273]

CORPAL, 2005:

unpublished

de Lezo J, Medina A, Pan M, et al. de Lezo J, Medina A, Pan M, et al. Drug-eluting stent for complexlesions: latest angiographic data from randomized rapamycinversus paclitaxel CORPAL study J Am Coll Cardiol 2005; 45: 75A.

Di Lorenzo et al., 2005:
unpublished
Di Lorenzo E, Varricchio A, Lanzillo T, et al. Paclitaxel and sirolimusstent implantation in patients with acute myocardial infarction (abstr) Circulation 2005;112:U538
Han, 2006:
Han YL, Wang XZ, Jing QM, Wang SL, Ma YY, Luan B [Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease] Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:123-6 [16626577]
ISAR-DESIRE (SES vs PES), 2005:
Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig A Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71 [15644543]
ISAR-DIABETES, 2005:
Dibra A, Kastrati A, Mehilli J, Pache J, Schhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schmig A Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70 [16105990]
ISAR-LEFT-MAIN, 2009:
Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schmig A Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009 May 12;53:1760-8 [19422982]
ISAR-SMART 3, 2006:
Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schmig A Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-6 [16401670]
ISAR-TEST-1, 2006:
Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schmig A Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-9 [16391155]
Kim, 2008:
Kim MH, Hong SJ, Cha KS, Park HS, Chae SC, Hur SH, Gwon HC, Bae JH, Lim DS Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv Cardiol 2008 Jun;21:225-31 [18341520]
LONG DES II, 2006:
Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006;114:2148-53 [17060388]
Petronio et al, 2007:
Petronio AS, De Carlo M, Branchitta G, Papini B, Ciabatti N, Gistri R, Cortese B, Gherarducci G, Barsotti A Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol 2007;49:539-46 [17276176]
REALITY, 2006:
Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904 [16493102]
SIRTAX (Windecker), 2005:
Windecker S, Remondino A, Eberli FR, Jni P, Rber L, Wenaweser P, Togni M, Billinger M, Tller D, Seiler C, Roffi M, Corti R, Stsch G, Maier W, Lscher T, Hess OM, Egger M, Meier B Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62 [16105989]
TAXi, 2005:
Goy JJ, Stauffer JC, Siegenthaler M, Benot A, Seydoux C A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005;45:308-11 [15653032]
Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benot A, Goy JJ Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. Catheter Cardiovasc Interv 2007 Aug 1;70:163-6 [17630653]
Tomai, 2008:
Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffr G, Prati F, Tamburino C, Ribichini F, Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. Diabetes Care 2008;31:15-9. [17909090] 10.2337/dc07-1377

Zhang (SES vs PES), 2006:

Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ni J, Fang YH, Zhang X, Shen WF One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl) 2006;119:165-8 [16455001]

DES-ISR, 0:

ongoing trial NCT00485030

Lipsia-Yukon-DM, 0:

ongoing trial NCT00368953

ENDEAVOR IV, 2009:

unpublished

Leon MB Endeavor Clinical Program Overview, FDA Advisory Panel, October 10th, 2007

Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, Yock PG, Honda Y, Kandzari DE, Leon MB, Fitzgerald PJ Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009 Aug;2:779-84 [19695548]

Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJ Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009 Dec;2:1208-18 [20129547] 10.1016/j.jcin.2009.10.008

Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv 2010;3:1043-50 [20965463] 10.1016/j.jcin.2010.07.008

ZoMaxx phase 2, 0:

ongoing trial NCT00140101

LEADERS, 2008:

Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jni P Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008 Aug 31;: [18765162]

Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jni P Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011 Dec 3;378:1940-8 [22075451] 10.1016/S0140-6736(11)61672-3

ISAR-TEST 4 (EES vs SES), :

Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schmig A, Mehilli J Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009 Oct;30:2441-9 [19720642] 10.1093/eurheartj/ehp352

SORT OUT IV, 2012:

[22308301]

Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, Villadsen AB, Junker A, Hansen KN, Kaltoft A, Maeng M, Pedersen KE, Kristensen SD, Btker HE, Ravkilde J, Sanchez R, Aare J, Madsen M, Srensen HT, Thuesen L, Lassen JF Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012 Mar 13;125:1246-55 [22308301]

Jensen LO, Thayssen P, Christiansen EH, Tilsted HH, Maeng M, Hansen KN, Kaltoft A, Hansen HS, Btker HE, Krusell LR, Ravkilde J, Madsen M, Thuesen L, Lassen JF 2-Year Patient-Related Versus Stent-Related Outcomes: The SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial. J Am Coll Cardiol 2012;60:1140-7 [22958957]

Leipzig, 0:

ongoing trial NCT00176397

MIDCAB Versus DES in Proximal LAD Lesions, 0:

ongoing trial NCT00299429

VELETI, 0:

ongoing trial NCT00289835

PERSEUS Workhorse, 2010:

ongoing trial NCT00484315

Allocco DJ, Cannon LA, Britt A, Heil JE, Nersesov A, Wehrenberg S, Dawkins KD, Kereiakes DJ A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program. Trials 2010 Jan 7;11:1 [20059766]

Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlf B, Kelly RY, Hua TA, Hester A, Pitt B Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010;56:77-85 [20620720] 10.1016/j.jacc.2010.02.046

3 stent

Trial	Treatments	Patients	Trials design and methods
Endeavor stent and three months of DAPT vs standard 12-month DAPT and other DES			
RESET [NCT01145079] n=NA follow-up:	-	-	

More details and results :

- antithrombotics for stent in all type of patients at http://www.trialresultscenter.org/go-Q151
- dual antiplatelet therapy for stent in all type of patients at http://www.trialresultscenter.org/go-Q578

References

RESET, :

Hong M-K A new strategy for discontinuation of dual antiplatelet therapy: real safety and efficacy of 3-month dual antiplatelet therapy following zotarolimuseluting stent implantation: RESET trial Presented at: American College of Cardiology Scientific Session; 2012, March 24; Chicago, IL

4 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
paclitaxel eluting stent vs balloon angioplasty			
ISAR-DESIRE (PES vs PTCA) , 2005 n=100/100 follow-up: 1y	TAXUS versus ballon angioplasty	In-stent restenosis. AP and/or positive test, previously stented, no AMI	Parallel groups open germany

continued...

Trial	Treatments	Patients	Trials design and methods
sirolimus eluting stent vs balloon angioplasty			
ISAR-DESIRE (SES vs PTCA) , 2005 n=100/100 follow-up: 1y	Cypher versus ballon angioplasty	In-stent restenosis. AP and/or positive test, previously stented, no AMI	Parallel groups open germany
stent vs balloon angioplasty			
Lincoff (EPISTENT) , 1999 [NCT00271401] n=794/796 follow-up: 6 months	stent followed by aspirin 325 mg, abciximab versus balloon angioplasty followed by aspirin 325 mg, abciximab	patients with ischaemic heart disease and suitable coronary-artery lesions	Parallel groups open USA, Canada
Hoher , 1999 n=42/43 follow-up: 6 months	Wiktor versus PTCA alone	patients with a thrombolysis in myocardial infarction grade 0 chronic coronary occlusion	Parallel groups open
Serruys Benestent , 1994 n=262/258 follow-up: 7 months	Palmaz-Schatz versus balloon angioplasty, aspirin 250-500 mg + dipyridamole 75 mgx3	Stable angina	Parallel groups Open Europe
Fischman STRESS , 1994 n=205/202 follow-up: 6 months	Palmaz-Schatz versus ballon angioplasty aspirin, dipyridamol	Stable angina	Parallel groups Open USA
Eeckout , 1996 n=42/42 follow-up: 6 months	Wiktor stent implantation versus conventional balloon angioplasty	Stable angina	Parallel groups open
Sirnes , 1996 n=58/59 follow-up: 6 months	Palmaz-Schatz versus PTCA alone	patients with a satisfactory result after successful recanalization by PTCA of a chronic coronary occlusion	Parallel groups open
Versaci , 1997 n=60/60 follow-up: 12 months	Palmaz-Schatz versus standard coronary angioplasty, aspirin and diltiazem indefinitely	patients with isolated stenosis of the proximal left anterior descending coronary artery	Parallel groups open Italy
Savage , 1998 n=108/107 follow-up: 6 months	Palmaz-Schatz stent versus standard balloon angioplasty	patients with new lesions in aortocoronary-venous bypass grafts	Parallel groups open
Erbel , 1998 n=191/192 follow-up: 6 months	Palmaz-Schatz versus standard balloon angioplasty	patients with clinical and angiographic evidence of restenosis after at least one balloon angioplasty	Parallel groups open
Rubartelli , 1998 n=56/54 follow-up: 9 months	Palmaz-Schatz stent implantation versus PTCA alone	patients with recanalized total occlusion	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
Hancock , 1998 n=30/30 follow-up: 6 months	Palmaz-Schatz versus angioplasty alone	patients with a total coronary occlusion successfully treated by PTCA	Parallel groups open
Serruys Benestent 2 , 1998 n=414/413 follow-up: 12 months	Heparin-coated Palmaz-Schatz versus ballon angioplastyaspirin >=100mg 6 month	Stable and unstable angina	Parallel groups Open Europe
Rodriguez , 1998 n=57/59 follow-up: 6 months	stent versus optimal PTCA	patients obtaining a good immediate angiographic result after percutaneous transluminal coronary angioplasty	Parallel groups open
Sievert , 1999 n=55/55 follow-up: 4 months	stent implantation versus angioplasty alone	Stable angina	Parallel groups open
Betriu , 1999 n=229/223 follow-up: 6 months (4y)	Palmaz-Schatz versus standard balloon angioplasty	Stable and unstable angina	Parallel groups open
Buller , 1999 n=202/208 follow-up: 6 months	Heparin-coated Palmaz-Schatz versus PTCA	patients with nonacute native coronary occlusions	Parallel groups open
Serruys , 2000 n=97/511 follow-up: 12 months	primary stenting versus balloon angioplasty	patients scheduled for single-vessel angioplasty	Parallel groups open
Di Marlo , 2000 n=370/365 follow-up: 12 months	elective stent implantation versus guided PTCA	Stable and unstable angina; no AMI inprevious 24 h	Parallel groups open
Kastrati , 2000 n=204/200 follow-up: 7 months	Multilink versus PTCA	Patients with symptomatic coronary artery disease with lesions situated in native coronary vessels between 2 and 2.8 mm in size	Parallel groups open
Witkowski , 2000 n=192/196 follow-up: 6 months	Palmaz-Schatz stent versus angioplasty	Symptomatic CAD; no AMI in previous 14 d	Parallel groups open
Lafont , 2000 n=125/126 follow-up: 6 months	systematic stenting versus provisional stenting (group 1, in which stenting was performed if postangioplasty coronary velocity reserve was <2.2 and/or residual stenosis >or =35% or as bail-out)	patients undergoing elective coronary angioplasty	Parallel groups open
Fluck , 2000 n=154/146 follow-up: 12 months	Wiktor stent versus balloon angioplasty	Symptomatic CAD; no AMI in previous 7 d	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
Dangas , 2000 n=31/66 follow-up: 8 months	elective stenting (Palmaz-Schatz stent) versus PTCA with prolonged perfusion balloon inflation	patients with discrete, de novo lesions in native coronary arteries >or =3 mm in diameter	Parallel groups open
Weaver , 2000 n=229/248 follow-up: 6 months	routine stent implantation (Palmaz-Schatz) versus balloon angioplasty and provisional stenting	patients undergoing single-vessel coronary angioplasty	Parallel groups open
Lotan , 2000 n=48/48 follow-up: 6 months	stent implantation (AVE Micro Stent) versus no further treatment	with total coronary artery occlusions who had an optimal PTCA result	Parallel groups open
Park , 2000 n=60/60 follow-up: 6 months (16 m)	elective stent placement (7-cell NIR stent) versus balloon angioplasty	patients with lesions in small coronary arteries (de novo, non-ostial lesion and reference diameter <3 mm)	Parallel groups open
Koning , 2001 n=192/189 follow-up: 6 months	stent implantation (beStent Small) versus standard balloon angioplasty	symptomatic patients with de novo focal lesion located on a small coronary segment vessel (<3 mm)	Parallel groups open
Doucet , 2001 n=169/182 follow-up: 6 months	stent implantation (beStent-Artist) versus angioplasty alone	symptomatic patients needing dilatation of 1 native coronary vessel between 2.3 and 2.9 mm in size	Parallel groups open
Moer , 2001 n=74/71 follow-up: 6 months	elective stenting treatment with the heparin (Hepamed)-coated beStent versus PTCA	patients with stable or unstable angina	Parallel groups open
abciximab-coated stent vs bare-metal stent			
Kim , 2010 n=93 follow-up: 6 mo (2y)	abciximab-coated stent versus bare metal stents	patients undergoing PCI for de novo coronary lesions	Parallel groups open Korea
dactinomycin eluting stent vs bare-metal stent			
ACTION , 2004 n=241/119 follow-up: 6 months	Multilink Tetra stent versus uncoated Multilink Tetra stent	Patients with stable angina pectoris orsilent ischemia and a single de novo lesion in a nativecoronary artery >=3.0 mm and <=4.0 mm in diameter thatcould be covered by an 18-mm stent	Parallel groups single-blind worldwide
everolimus eluting stent vs bare-metal stent			
BASKET-PROVE (EES) , 2010 [ISRCTN72444640] n=774/765 follow-up: 2 years	second generation everolimus-eluting stent versus BMS	patients needing stents 3.0 mm or larger	open Switzerland, Denmark, Austria, Italy

continued...

Trial	Treatments	Patients	Trials design and methods
FUTURE I , 2004 n=27/15 follow-up: 12 months	everolimus coated S-Stent versus S-Stent	de novo coronary lesions	Parallel groups single-blind Germany
FUTURE II , 2006 *unpublished* n=43/21 follow-up: 6 months	CHAMPION versus bare-metal stent	Patients with de novo lesions in vessels with a reference diameter of 2.75-4.0 mm and length </= 18 mm	Parallel groups double-blind
SPIRIT I , 2005 [NCT00180453] n=28/32 follow-up: 6 months (5yr)	everolimus eluting sent, XIENCE versus bare etal stent, MULTI-LINK VISION	patients with de novo native coronary artery lesions	Parallel groups single-blind
paclitaxel eluting stent vs bare-metal stent			
Erglis , 2007 n=53/50 follow-up: 6 months	IVUS-guided paclitaxel-eluting stent (Taxus Express) after lesion pre-treatment with cutting balloon versus IVUS-guided bare-metal (Express or Liberte) after lesion pre-treatment with cutting balloon	percutaneous coronary intervention for unprotected left main artery stenosis	Parallel groups open
HAAMU-STENT , 2006 *unpublished* n=70/75 follow-up: 12 months	Taxus Express versus Bare-metal-stent	AMI - STEMI patients undergoing PCI	Parallel groups open Finland
HORIZONS-AMI Stent , 2008 n=2257/749 follow-up: 1 year	paclitaxel-eluting stents (Taxus) versus BMS (Express)	ST-elevation myocardial infarction	Factorial plan open
PASSION , 2006 [ISRCTN65027270] n=310/309 follow-up: 12 months (5y)	Taxus Express2 versus Express2 or Libert	Myocardial Infarction with ST-Segment Elevation	Parallel groups open The Netherlands
SCORE , 2004 n=126/140 follow-up: 12 months	QuaDDS stents (paclitaxel) versus uncoated control stents	patients with focal, de novo coronary lesions	Parallel groups open Worldwide
SOS , 2008 [NCT00247208] n=41/39 follow-up: 1.5y median	Paclitaxel-Eluting Stent (Taxus) versus bare metal stent (Express-2)	patients undergoing percutaneous coronary intervention of saphenous vein bypass grafts	Parallel groups open USA, Greece

continued...

Trial	Treatments	Patients	Trials design and methods
TAXUS I , 2003 n=31/30 follow-up: 12 months	TAXUS NIR versus NIR stent	Stable or unstable AP, silent ischaemia; single de novo or restenotic coronary lesions	Parallel groups double-blind Germany
TAXUS II , 2003 [NCT00299026] n=266/270 follow-up: 12 months	TAXUS versus NIR stent	Stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99% ,	Parallel groups double-blind Global
TAXUS II (diabetics) , 2003 *unpublished* n=37/41 follow-up: 12 months	TAXUS versus NIR stent	Diabetic patients with stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99% ,	Parallel groups double-blind Europe
TAXUS IV , 2004 [NCT00292474] n=662/652 follow-up: 9 months	TAXUS versus EXPRESS	Stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)	Parallel groups double-blind United States
TAXUS IV (diabetics) , 2005 [NCT00292474] n=155/163 follow-up: 9 months	TAXUS versus EXPRESS	Diabetic patients with stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)	Parallel groups double-blind United States
TAXUS V (all patients) , 2005 [NCT00301522] n=577/579 follow-up: 9 months	TAXUS versus bare metal EXPRESS-2	Stable or unstable AP, silent ischaemia with single coronary artery stenosis including complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)	Parallel groups double-blind United States
TAXUS V (diabetics) , 2005 n=178/171 follow-up: 9 months	TAXUS versus BMS	Diabetic patients with stable or unstable AP, silent ischaemia with complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)	Parallel groups double-blind United States
TAXUS V small vessels sub groups n=NA follow-up:	paclitaxel-eluting stents versus bare metal stents	patients who underwent stent implantation in a single coronary artery stenosis (vessel diameter, 2.25-4.0 mm; lesion length, 10-46 mm), subgroup of small vessel patients	
TAXUS VI , 2005 [NCT00297804] n=219/227 follow-up: 9 months (2y)	TAXUS versus Express2 stent	Stable or unstable AP, silent ischaemia with long, complex coronary artery lesions	Parallel groups double-blind Europe

continued...

Trial	Treatments	Patients	Trials design and methods
TAXUS VI (diabetics) , 2005 [NCT00297804] n=39/50 follow-up: 9 months	TAXUS versus Express2 stent	Diabetic patients with stable or unstable AP, silent ischaemia with long, complex coronary artery lesions	Parallel groups double-blind Europe
BASKET-SAVAGE *ongoing* [NCT00595647] n=NA follow-up:	Taxus versus Libert	percutaneous coronary interventions of saphenous vein grafts	open
paclitaxel, non-polymeric eluting stent vs bare-metal stent			
ASPECT , 2003 [NCT00196079] n=117/58 follow-up: 6 months	coated Supra-G stent versus Supra-G stent	patientswith discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter)	Parallel groups double-blind
DELIVER , 2004 n=524/519 follow-up: 9 months	non-polymer-based paclitaxel-coated ACHIEVE stent versus stainless steel Multi-Link (ML) PENTA stent	patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels	Parallel groups single-blind US
ELUTES , 2004 n=152/38 follow-up: 12 months	coated V-Flex Plus versus V-Flex Plus	single de novo type A or type B1 lesions 15 mm length in a nativecoronary artery	Parallel groups open Europe
PATENCY , 2002 *unpublished* n=24/26 follow-up: 9 months	Logic PTX paclitaxel Eluting CoronaryStents versus uncoated control stents	Patients with de novo lesions of 2.7- to 4.0-mm diameter and 25-mm length received 3.0, 3.5, or 4.0 mm 10- or 15-mm	Parallel groups double blind
sirolimus eluting stent vs bare-metal stent			
BASKET-PROVE (SES) , 2010 [ISRCTN72444640] n=775/765 follow-up: 2 years	first-generation sirolimus-eluting stent versus BMS	patients needing stents 3.0 mm or larger	Parallel groups open Switzerland, Denmark, Austria, Italy
C-SIRIUS , 2004 [NCT00381420] n=50/50 follow-up: 9 months	coated Bx-VELOCITY versus Bx-VELOCITY	Stable or unstable AP, silent ischaemia	Parallel groups double-blind Canada
DEBATER (SES vs BMS) , 2009 n=424/446 follow-up: 1 y	sirolimus-eluting stents versus bare-metal stents	patients undergoing PCI for STEMI withon 12 hours	Factorial plan

continued...

Trial	Treatments	Patients	Trials design and methods
DECODE , 2005 *unpublished* [NCT00489164] n=54/29 follow-up: 1 year	CYPHER (Up to 3 stents per patient were allowed) versus Bx VELOCITY (Up to 3 stents per patient were allowed)	Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels	Parallel groups open US, Asia/Pacific
DESSERT , 2008 n=75/75 follow-up: 12 months	Cypher andCypher Select versus Sonic (Cordis)	de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >3 months	Parallel groups single-blind Italy
DIABETES , 2005 n=80/80 follow-up: 9 months	Cypher versus Bx Velocity/Sonic	de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm	Parallel groups open Spanish
Daz de la Llera , 2007 n=60/54 follow-up: 1y	sirolimus-eluting stents versus uncoated stents	primary percutaneous coronary intervention for acute myocardial infarction with ST-segment elevation	Parallel groups open Spain
E-SIRIUS , 2003 [NCT00235144] n=175/177 follow-up: 9 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment	Parallel groups open Europe
GISSOC II , 2010 [NCT00220558] n=78/74 follow-up: 8 months	Sirolimus Eluting Stent versus Bare Metal Stent	patients with Chronic Total Occlusion older than 1 month, and successful recanalization	Parallel groups open Italy
Kochiadakis , 2007 n=38/43 follow-up: 4.8 months (mean)	sirolimus-eluting stents versus bare metal stent	one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm	Parallel groups open Greece
MISSION , 2008 [ISRCTN62825862] n=158/152 follow-up: 12 months	Cypher versus Vision	primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h)	Parallel groups single-blind the Netherlands
Ortolani et al , 2007 n=NA follow-up: 9 months	Cypher versus Vision	symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent	Parallel groups single-blind
Pache et al , 2005 n=250/250 follow-up: 12 months	Cypher versus BeStent 2	with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels	Parallel groups open Germany

continued...

Trial	Treatments	Patients	Trials design and methods
Pasceri , 2003 *unpublished* n=NA follow-up: 12 months	-	-	Parallel groups
PRISON II , 2006 [NCT00258596] n=100/100 follow-up: 6 months	Cypher versus BxVelocity	Chronic total occlusion, positive exercise stress test	Parallel groups single-blind Belgium
RAVEL , 2002 [NCT00233805] n=120/118 follow-up: 12 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery	Parallel groups double-blind Global
Ravel (diabetics) , 2004 n=19/25 follow-up: 6 months	coated Bx velocity versus Bx VELOCITY	sub groups of diabetic patients with de novo native coronary arterylesions 2.5 to 3.5 mm in diameter by visualassessment that could be covered by an 18-mm stent	Parallel groups NA Europe
RRISC , 2006 [NCT00263263] n=38/37 follow-up: 6 months (3 years)	Cypher versus BX-Velocity	Stable or unstable AP, with previous coronary artery bypass surgery and degenerated vein grafts	Parallel groups open Belgium, The netherlands
SCANDSTENT , 2006 [NCT00151658] n=163/159 follow-up: 7 months	Cypher versus Sonic	Stable or unstable AP, recent AMI (non ST-elevation); with one or more de novo complex lesions in native coronary vessels (occluded, bifurcational, ostial or angulated)	Parallel groups open Denmark
SCANDSTENT (subgroup) , 2006 n=64/63 follow-up: 17 mo (angiography 7 mo)	SES implanted after successful recanalization versus BMS implanted after successful recanalization	patients with coronary artery disease and a total coronary occlusion >or = 15 mm in length	Parallel groups open
SCORPIUS , 2007 [NCT00495898] n=98/102 follow-up: 12 months	Cypher versus Bx-Velocity	patients with diabetes and de novo coronary artery lesions	Parallel groups open Germany
SES-SMART , 2004 n=129/128 follow-up: 8 months	Cypher versus Bx Sonic	Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test	Parallel groups single-blind Italian

continued...

Trial	Treatments	Patients	Trials design and methods
SES-SMARt (diabetics) , 2005 n=29/45 follow-up: 8 months	Cypher versus Bx Sonic	Diabetic patients with de novo target lesion <=2.75 mm in diameter in a native coronary artery that could be completely covered by a single stent (maximum length 33 mm)	Parallel groups single-blind Italy
SESAMI , 2007 [NCT00288210] n=160/160 follow-up: 12 months	Cypher versus BX stent, Cordis	AMI	Parallel groups open Italy
SIRIUS , 2003 [NCT00232765] n=533/525 follow-up: 9 months	SES versus Bx Velocity	Stable or unstable AP, signs of myocardial ischaemia	Parallel groups double-blind United States
SIRIUS (diabetics) , 2003 n=131/148 follow-up: 12 months	SES versus BMS	sub group of diabetics patients of SIRIUS study	Parallel groups double-blind US
TYPHOON , 2006 [NCT00232830] n=356/359 follow-up: 12 months	Cypher or CypherSelect versus any commerciallyavailable uncoated stent	AMI	Parallel groups open Worldwide (15 countries)
BASKET-PROVE , 2008 *ongoing* n=NA follow-up:	Cypher versus Vision	-	
titanium-nitride-oxide coated stent vs bare-metal stent			
TINOX , 2005 n=45/47 follow-up: 6 mo	titanium-nitride-oxide coated stents versus stainless steel stents of similar design	-	Parallel groups open Switzerlanf, Germany
zotarolimus eluting stent vs bare-metal stent			
ENDEAVOR II , 2006 n=598/599 follow-up: 12 months	AVE Zotarolimus-Eluting Driver versus Driver	single de novo native coronary artery stenosis	Parallel groups double-blind worldwide
PCI with or without stent vs medical treatment			
TIME , 2001 n=NA follow-up:	coronary angiography and revascularisation versus optimised medical therapy	patients aged 75 years or older with chronic angina of at least Canadian Cardiac Society class II despite at least two antianginal drugs	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
AVERT , 1995 n=177/164 follow-up: 1.5y	angioplasty versus atorvastatin at 80 mg per day	Angina or asymptomatic, MI orunstable angina but not within 14 days,no triple vessel disease	Parallel groups open
Dakik , 1998 n=19/22 follow-up: 1y	PTCA versus intensive medical therapy	stable survivors of AMI	Parallel groups open
MASS II , 2007 n=205/203 follow-up: 5y	PCI versus medical therapy	patients with multivessel coronary artery disease with stable angina and preserved ventricular function	Parallel groups open
COURAGE , 2007 [NCT00007657] n=1149/1138 follow-up: median 4.6 y	PCI coupled with optimal medical therapy versus optimal medical therapy aloneitm	patients with stable coronary artery disease	Parallel groups open Canada, US
ALKK , 2003 n=149/151 follow-up: 4.7y	angioplasty versus medical therapy	patients with single vessel disease of the infarct vessel and no or minor angina pectoris in the subacute phase (1 to 6 weeks) after an acute myocardial infarction	Parallel groups open Germany
Hambrecht , 2004 n=50/51 follow-up: 1y	PCI versus 12 months of exercise training (20 minutes of bicycle ergometry per day)	male patients aged 70 years	Parallel groups open
Bech , 2001 n=90/91 follow-up: 2y	PTCA versus deferral of PTCA	patients with planned PTCA and no documented ischemia and with coronary pressurederived fractional flow reserve >0.75	Parallel groups open
ISCHEMIA *ongoing* n=NA follow-up:	invasive strategy, consisting of early routine cardiac catheterization followed by revascularization plus optimal medical therapy (OMT) and lifestyle changes versus conservative strategy of optimal medical therapy and lifestyle changes in which invasive procedures will be performed only after failure of OMT	patients with stable ischemic heart disease and moderate to severe ischemia	Parallel groups open-label
sirolimus eluting stent vs PTCA			
CRISTAL [NCT00323895] n=NA follow-up:	sirolimus-eluting stent versus balloon re-percutaneous transluminal coronary angioplasty	Intra-Des Restenosis	

continued...

Trial	Treatments	Patients	Trials design and methods
RIBS-II , 2008 n=76/74 follow-up: >1 year	sirolimus-eluting stents versus Balloon angioplasty	patients with bare metal in-stent restenosis	Parallel groups open Spanish
dexamethasone eluting stent vs bare-metal stent			
FEMH-93005 *ongoing* [NCT00190099] n=NA	-	-	
drug-eluting stents vs bare-metal stent			
DEDICATION , 2008 [NCT00192868] n=313/313 follow-up: 8 mo (15 mo, 3y)	DES currently used with or without distal protection versus BMS with or without distal protection	patients referred within 12 hours from symptom onset of an ST-elevation myocardial infarction	Factorial plan open Denmark.
PASEO , 2009 n=180/90 follow-up: 4.3 years	paclitaxel-eluting stents and sirolimus-eluting stents versus bare metal stent	patients with ST-elevation myocardial infarction within 12 hours from symptom onset	Parallel groups open
ISAR-CABG *ongoing* [NCT00611910] n=NA follow-up:	DES versus BMS	Bypass Graft Lesions	open
Genous stent vs bare-metal stent			
GENIUS-STEMI , 2009 n=50/50 follow-up: 6 months	endothelial progenitor cell capture stent versus cobalt chromium stent	patients with ST-elevation myocardial infarction	Parallel groups NA
TRIAS-Low-Risk *ongoing* n=NA	-	-	
crush stenting vs culotte stenting			
Nordic Bifurcation Stent Technique Study *ongoing* [NCT00292305] n=NA follow-up:	crush stenting versus culotte stenting	bifurcation lesions	
sirolimus eluting stent vs cutting ballon angioplasty			
FOCUS *ongoing* [NCT00485004] n=NA follow-up:	sirolimus-eluting implantation cypher versus cutting balloon angioplasty	focal in-stent restenosis after drug-eluting stent	
sirolimus eluting stent vs brachytherapy			

continued...

Trial	Treatments	Patients	Trials design and methods
SISR , 2007 [NCT00231257] n=259/125 follow-up: 12 months	Sirolimus-eluting stents versus brachytherapy	restenosis within a bare metal stent	Parallel groups open US and Canadian
paclitaxel eluting stent vs CABG			
SYNTAX , 2009 [NCT00114972] n=903/897 follow-up: 1 year	paclitaxel (taxus Express SR) versus Coronary Artery Bypass Surgery (on- or off-pump bypass)	patients with previously untreated three-vessel or left main coronary artery disease (or both) (complex lesions)	Parallel groups open
PCI with drug-eluting stents vs CABG			
SYNTAX (diabetic) , 2010 [NCT00114972] n=NA follow-up: 1 year	paclitaxel-eluting stents versus surgical revascularization	sub group of diabetic patients with left main and/or 3-vessel disease	Parallel groups
FREEDOM , 2012 [NCT00086450] n=953/947 follow-up: 3.8 yrs (median)	percutaneous coronary stenting versus CABG	patients with diabetes and multivessel coronary artery disease	Parallel groups open international
PCI withdrug-eluting stents vs CABG			
Hong , 2005 n=119/70 follow-up: 9 months	drug-eluting stents versus invasive direct coronary artery bypass (MIDCAB) surgery	proximal left anterior descending (LAD) coronary artery stenosis	Parallel groups open
VA CARDS *ongoing* [NCT00326196] n=NA follow-up:	percutaneous coronary stenting with drug eluding stents versus CABG	angiographically significant coronary artery disease in diabetes	Parallel groups open
stent vs CABG			
ARTS , 2001 n=600/605 follow-up: 1 year	Palmaz-Schatz Crown/Cross flex (Cordis) versus Conventional CABG	Multi vessel disease with 2 or more de novo lesion in different major arteries Total occlusion <1month	parallel group open International
CARDia (PCI) , 2008 [ISRCTN19872154] n=256/254 follow-up: 1 y	PCI plus stenting (and routine abciximab) versus CABG	Patients with diabetes and symptomatic multivessel coronary artery disease or complex single-vessel disease.	Parallel groups open UK, Ireland
ERACI II , 2003 n=225/225 follow-up: 30d, 1year	Gianturco Robin II (Cook) Primary device versus Conventional CABG	multi vessel disease Angina CSS III-IV; no angina but large area of heart at risk; unstable =1 vessel to be treated Lesion>3.0mm	parallel group open Argentinad

continued...

Trial	Treatments	Patients	Trials design and methods
LEMANS , 2002 [NCT00375063] n=52/53 follow-up: 1y	unprotected left main stenting versus coronary artery bypass grafting	patients with unprotected left main coronary artery stenosis	Parallel groups open Poland
MASS II , 2007 n=205/203 follow-up: 5y (1y)	PCI (73% stent) versus CABG	patients with multivessel coronary artery disease with stable angina and preserved ventricular function	Parallel groups open South America
Myoprotect , 2004 n=23/21 follow-up: 1 year	percutaneous transluminal coronary angioplasty/stent versus CABG	patients with symptomatic main-stem and main-stem-equivalent lesions with substantially increased risk for bypass surgery	Parallel groups open Europe
SOS , 2002 [NCT00475449] n=488/500 follow-up: 3 years	Stent versus CABG	multiple vessel disease Symptomatic 1 or more vessel suitable for stenting	parallel group open Canada, United Kingdom, Europe
stent vs E-ACAB			
Cisowski n=50/50 follow-up: 2 years	Tristar, Tera, Penta (Guidant) (Cordis) versus endoscopic atraumatic coronary artery bypass grafting	single vessel disease ACC/AHA A or B lesion in proximal LAD Angina CCS II or higher Lesion diameter 3 mm orgreater/length 20mm or greater	parallel group open Poland
everolimus eluting stent vs everolimus eluting stent			
PLATINUM , 2011 [NCT00823212] n=768/762 follow-up: 12 months	platinum chromium everolimus-eluting stent versus cobalt chromium everolimus-eluting stent	patients with up to 2 de novo atherosclerotic coronary artery lesions	Parallel groups single-blind worldwide
zotarolimus eluting stent vs everolimus eluting stent			
RESOLUTE All comers , 2010 [NCT00617084.)] n=1140/1152 follow-up: 12 months (5y)	zotarolimus-eluting stent versus everolimus-eluting stent (Xience)	adult patients with chronic, stable coronary artery disease or acute coronary syndromes, including myocardial infarction with or without ST-segment elevation	Parallel groups open
TWENTE , 2012 [NCT01066650] n=NA follow-up: 1 year	zotarolimus-eluting stent versus everolimus-eluting stent	"real-world" patients	Parallel groups single (patient-blinded)
stent vs MIDCAB			
Diegeler , 2002 n=110/110 follow-up: 5 years	Various stents versus minimally invasive direct coronary artery bypass (off-pump proceedure)	single vessel disease Lesion =75% stenosis in proximal LAD or between origin of left circumflex and 1st septal branch	parallel group open Germany

continued...

Trial	Treatments	Patients	Trials design and methods
Drenth , 2002 n=51/51 follow-up: 6 months, 3 years	Stent type not reported versus minimally invasive direct coronary artery bypass (off-pump proceedure	single vessel disease Angina II Lesion (Grade B2 or C) of proximal LAD Suitable for CABG or stenting	parallel group open Netherlands
Grip , 2001 n=28/25 follow-up:	Stent type not reported versus minimally invasive direct coronary artery bypass (off-pump proceedure)	single vessel disease engaging LAD Stable or unstable angina	parallel group open Sweden
Kim , 2005 n=50/50 follow-up: 2 years	Stent versus MIDCAB using ministernotomy	patients with isolated proximal left anterior descending artery disease	Parallel groups open Korea
SIMA , 2000 n=62/59 follow-up: 2.4 years	Any CE marked, but Palmaz-Schatz recommended versus Conventional CABG or minimally invasive direct coronary artery bypass (off-pump proceedure) (10% of surgical procedures	single vessel disease Symptomatic or silent ischaemia 1 LAD lesion Ejection fraction >45% Vessel >3.0mm	parallel group open Europe
stent vs OPCAB			
OCTOSTENT , 2003 [NCT00975858] n=138/142 follow-up: 1 year	Stent type not reported versus off-pump coronary artery bypass	multi or single vessel disease Moderate LV function CABG or stenting to be considered feasible	Parallel groups open Europe
CoStar stent vs paclitaxel eluting stent			
Costar II , 2008 [NCT00165035] n=989/686 follow-up: 8 months (1 year)	CoStar stent (Conor MedSystems) PES versus Taxus (Boston Scientific) PES	patient undergoing percutaneous coronary intervention for a single lesion per vessel in up to three native epicardial vessels	Parallel groups single-blind US, Germany, Belgium, and New Zealand
COSTAR II diabetic (sub group) , 2008 n=271/271 follow-up: 8 months	CoStar stent (PES) versus Taxus stent (PES)	patients with de novo single- or multivessel coronary disease	Parallel groups open
everolimus eluting stent vs paclitaxel eluting stent			
COMPARE , 2009 [NCT01016041] n=897/903 follow-up: 1 y (2y)	polymer based, everolimus-eluting stent (Xience V) versus polymer-based, paclitaxel-eluting stent (Taxus Liberte)	unselected patients	Parallel groups open the Netherlands

continued...

Trial	Treatments	Patients	Trials design and methods
SPIRIT II , 2006 *unpublished* [NCT00180310] n=223/77 follow-up: 6 months	everolimus eluting stent, XIENCE V versus placitaxel eluting stent, TAXUS EXPRESS2	De novo lesions (maximim two)	Parallel groups single-blind (patient)
SPIRIT III , 2008 [NCT00180479] n=669/333 follow-up: 12 months	everolimus-eluting stent, XIENCE V versus paclitaxel-eluting stent, Taxus	lesions 28 mm or less in length and with reference vessel diameter between 2.5 and 3.75 m	Parallel groups single-blind US
SPIRIT III (small vessel subgroup) , 2009 n=160/59 follow-up: 9 months	2.5-mm everolimus-eluting stent versus 2.5-mm paclitaxel-eluting stent	patients included in SPIRIT III that received at least one 2.5-mm stent	Parallel groups open
SPIRIT IV , 2010 [NCT00307047] n=2458/1229 follow-up: 1 y (2y)	XIENCE V Everolimus Eluting Coronary Stent System versus TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System (TAXUS).	patients with de novo native coronary artery lesions and reference vessel diameters between 2.5 mm to 4.25 mm and lesion lengths <= 28 mm	Parallel groups 270 days (5 years) USA

More details and results :

- myocardial revascularization for coronary artery disease in all type of patient at http://www.trialresultscenter.org/go-Q26
- myocardial revascularization for coronary artery disease in diabetic patients at http://www.trialresultscenter.org/go-Q30
- myocardial revascularization for coronary artery disease in multivessels disease at http://www.trialresultscenter.org/go-Q31
- myocardial revascularization for coronary artery disease in single vessel disease at http://www.trialresultscenter.org/go-Q32
- Drug eluting stent for coronary artery disease in all type of patients at http://www.trialresultscenter.org/go-Q206
- Drug eluting stent for coronary artery disease in diabetic patients at http://www.trialresultscenter.org/go-Q207
- Drug eluting stent for coronary artery disease in acute myocardial infarction at http://www.trialresultscenter.org/go-Q208
- Drug eluting stent for coronary artery disease in long or complex lesion at http://www.trialresultscenter.org/go-Q209
- Drug eluting stent for coronary artery disease in bypass graft lesion at http://www.trialresultscenter.org/go-Q210
- Drug eluting stent for coronary artery disease in in stent restenosis at http://www.trialresultscenter.org/go-Q211
- Drug eluting stent for coronary artery disease in unprotected left main artery stenosis at http://www.trialresultscenter.org/go-Q212
- Drug eluting stent for coronary artery disease in bifurcation lesion at http://www.trialresultscenter.org/go-Q214
- Drug eluting stent for coronary artery disease in unparticular patients at http://www.trialresultscenter.org/go-Q215
- Drug eluting stent for coronary artery disease in total occlusion at http://www.trialresultscenter.org/go-Q216
- Drug eluting stent for coronary artery disease in small vessels at http://www.trialresultscenter.org/go-Q217

References

ISAR-DESIRE (PES vs PTCA), 2005:

Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig A Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71 [15644543]

ISAR-DESIRE (SES vs PTCA), 2005:

Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig A Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71 [15644543]

Lincoff (EPISTENT), 1999:

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999 Jul 29;341:319-27 [10423466]

—Z Lancet 1998 Jul 11;352:87-92 [9672272]

Hoher, 1999:

Hoher M, Wohrle J, Grebe OC, Kochs M, Osterhues HH, Hombach V, Buchwald AB A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol 1999 Sep;34:722-9 [10483953]

Serruys Benestent, 1994:

Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95 [8041413]

Macaya C, Serruys PW, Ruygrok P, Suryapranata H, Mast G, Klugmann S, Urban P, den Heijer P, Koch K, Simon R, Morice MC, Crean P, Bonnier H, Wijns W, Danchin N, Bourdonnec C, Morel MA Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol 1996;27:255-61 [8557891]

Fischman STRESS, 1994:

Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501 [8041414]

Eeckout, 1996:

Eeckhout E, Stauffer JC, Vogt P, Debbas N, Kappenberger L, Goy JJ Comparison of elective Wiktor stent placement with conventional balloon angioplasty for new-onset lesions of the right coronary artery. Am Heart J 1996 Aug;132:263-8 [8701885]

Sirnes, 1996:

Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus J Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol 1996 Nov 15;28:1444-51 [8917256]

Versaci , 1997:

Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997;336:817-22 [9062089]

Savage, 1998:

Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg S Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997 Sep 11;337:740-7 [9287229]

Erbel, 1998:

Erbel R, Haude M, Hopp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998 Dec 3;339:1672-8 [9834304]

Rubartelli, 1998:

Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini G Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. J Am Coll Cardiol 1998 Jul;32:90-6 [9669254]

Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini G Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. J Am Coll Cardiol 1998 Jul;32:90-6 [9669254]

Hancock, 1998:

Hancock J, Thomas MR, Holmberg S, Wainwright RJ, Jewitt DE Randomised trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries. Heart 1998 Jan;79:18-23 [9505913]

Serruys Benestent 2, 1998:

Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) Lancet 1998;352:673-81 [9728982]

Rodriguez, 1998:

Rodriguez A, Ayala F, Bernardi V, Santaera O, Marchand E, Pardinas C, Mauvecin C, Vogel D, Harrell LC, Palacios IF Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results. J Am Coll Cardiol 1998 Nov;32:1351-7 [9809947]

Sievert, 1999:

Sievert H, Rohde S, Utech A, Schulze R, Scherer D, Merle H, Ensslen R, Schrader R, Spies H, Fach A Stent or angioplasty after recanalization of chronic coronary occlusions? (The SARECCO Trial). Am J Cardiol 1999 Aug 15;84:386-90 [10468073]

Betriu, 1999:

Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delcan JL, Garcia E, Calabuig J Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999 Nov 1;34:1498-506 [10551699]

Buller, 1999:

Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, Anderson TJ, Knudtson ML, Marquis JF, Suzuki T, Cohen EA, Fox RS, Teo KK Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999 Jul 20;100:236-42 [10411846]

Serruys, 2000:

Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, Vrints C, Probst P, Seabra-Gomes R, Simpson I, Voudris V, Gurne O, Pijls N, Belardi J, van Es GA, Boersma E, Morel MA, van Hout B Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. Circulation 2000 Dec 12;102:2930-7 [11113042]

Di Marlo, 2000:

Di Mario C, Moses JW, Anderson TJ, Bonan R, Muramatsu T, Jain AC, Suarez de Lezo J, Cho SY, Kern M, Meredith IT, Cohen D, Moussa I, Colombo A Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint STenting INternational Investigation). Circulation 2000 Dec 12;102:2938-44 [11113043]

Kastrati, 2000:

Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann FJ A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000 Nov 21;102:2593-8 [11085962]

Witkowski, 2000:

Witkowski A, Ruzyllo W, Gil R, Gorecka B, Purzycki Z, Kosmider M, Polonski L, Lekston A, Gasior M, Zmudka K, Pieniazek P, Buszman P, Drzewiecki J, Ciecwierz D, Sadowski Z A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators. Am Heart J 2000 Aug;140:264-71 [10925341]

Lafont, 2000:

Lafont A, Dubois-Rande JL, Steg PG, Dupouy P, Carrie D, Coste P, Furber A, Beygui F, Feldman LJ, Rahal S, Tron C, Hamon M, Grollier G, Commeau P, Richard P, Colin P, Bauters C, Karrillon G, Ledru F, Citron B, Marie FN, Kern M The French Randomized Optimal Stenting Trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. F.R.O.S.T. Study Group. J Am Coll Cardiol 2000 Aug;36:404-9 [10933349]

Fluck, 2000:

Fluck DS, Chenu P, Mills P, Davies A, Street J, Paul E, Balcon R, Layton CA Is provisional stenting the effective option? The WIDEST study (Wiktor stent in de novo stenosis). Widest Trial Investigators' Group. Heart 2000 Nov;84:522-8 [11040014]

Dangas, 2000:

Dangas G, Ambrose JA, Rehmann D, Marmur JD, Sharma SK, Hemdal-Monsen C, Sanborn TA, Fischman DL Balloon optimization versus stent study (BOSS): provisional stenting and early recoil after balloon angioplasty. Am J Cardiol 2000 Apr 15;85:957-61 [10760334]

Weaver, 2000:

Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PP, Henry T, D'Haem C, Clark VL, Martin JS, Cohen DJ, Neil N, Every NR Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet 2000 Jun 24;355:2199-203 [10881893]

Lotan, 2000:

Lotan C, Rozenman Y, Hendler A, Turgeman Y, Ayzenberg O, Beyar R, Krakover R, Rosenfeld T, Gotsman MS Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. Eur Heart J 2000 Dec;21:1960-6 [11071802]

Park, 2000:

Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY, Park SJ Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 2000 Nov;21:1785-9 [11052843]

Koning, 2001:

Koning R, Eltchaninoff H, Commeau P, Khalife K, Gilard M, Lipiecki J, Coste P, Bedossa M, Lefevre T, Brunel P, Morice MC, Maillard L, Guyon P, Puel J, Cribier A Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. Circulation 2001 Oct 2;104:1604-8 [11581136]

Doucet, 2001:

Doucet S, Schalij MJ, Vrolix MC, Hilton D, Chenu P, de Bruyne B, Udayachalerm W, Seth A, Bilodeau L, Reiber JH, Harel F, Lesperance J Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation 2001 Oct 23;104:2029-33 [11673341]

Moer, 2001:

Moer R, Myreng Y, Molstad P, Albertsson P, Gunnes P, Lindvall B, Wiseth R, Ytre-Arne K, Kjekshus J, Golf S Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol 2001 Nov 15;38:1598-603 [11704369]

Kim, 2010:

Kim SS, Hong YJ, Jeong MH, Kim W, Kim HK, Ko JS, Lee MG, Sim DS, Park KH, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Song SJ, Cho DL, Kang JC Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease. Circ J 2010;74:442-8 [20103970]

ACTION, 2004:

Serruys PW, Veldhof S, Stuteville M, et al Actinomycin-elutingstent improves outcome by reducing neointimal hyperplasia Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002

Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schmig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH, Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel K, Johnson R, Coleman L, Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 2004 Oct 6;44:1363-7 [15464314]

BASKET-PROVE (EES), 2010:

Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. N Engl J Med 2010 Nov 16;: [21080780] 10.1056/NEJMoa1009406

FUTURE I, 2004:

Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71 [15123533]

FUTURE II, 2006:

unpublished

Grube E, Lansky A, Mehran R, Fitzgerald P, Ho Multicenter evaluation of the bioabsorbable polymer-basedeverolimus-eluting stent: FUTURE-2 trial Transcatheter-Cardiovascular Therapeutic Annual Meeting, September, 2003

Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Mller R, Strger H, Hauptmann KE, Grube E Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006 Aug 15;98:464-9 [16893698]

Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004 May 11;109:2168-71 [15123533]

SPIRIT I, 2005:

Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005 May;1:58-65 [19758878]

Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention 2005 Nov;1:266-72 [19758915]

Tsuchida K, Garca-Garca HM, Ong AT, Valgimigli M, Aoki J, Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PW Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv 2006 Feb;67:188-97 [16400664]

Erglis, 2007:

Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I, Strazdins U, Saltups A A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007;50:491-7 [17678730]

HAAMU-STENT, 2006:

unpublished

Tierala I, Syvaenne M, Kupari M Randomised comparison of apaclitaxel-eluting and a bare metal stent in STEMI-PCI. TheHAAMU-STENT-study Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics; Washington, DC;Oct 2227, 2006. Abstract 178.

HORIZONS-AMI Stent, 2008:

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011 Jun 25;377:2193-2204 [21665265] 10.1016/S0140-6736(11)60764-2

PASSION, 2006:

Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13 [16971717]

Dirksen MT, Vink MA, Suttorp MJ, Tijssen JG, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ EuroIntervention 2008 May;4:64-70 [19112781]

SCORE, 2004:

Stone GW. Adverse outcomes from a taxane-loaded polymericsleeved stent: final results from the SCORE Tria AmericanCollege of Cardiology Scientific Session, March, 2002

Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell ME High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004 Oct 6;44:1368-72 [15464315]

SOS, 2008:

Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009 Mar 17;53:919-28 [19281920]

Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 2011;4:176-82 [21349456] 10.1016/j.jcin.2010.10.003

TAXUS I, 2003:

Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42 [12515740]

Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003 Jan 7;107:38-42 [12515740]

TAXUS II, 2003:

Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94 [12900339]

Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, Dudek D, Baim DS Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009 Oct 13;120:1498-504 [19786634]

TAXUS II (diabetics), 2003:

unpublished

Hermiller J. Diabetic results: Taxus II, IV and VI TCT [0]

TAXUS IV, 2004:

Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31 [14724301]

Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents 5-Year Final Results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009 Dec;2:1248-59 [20129552] 10.1016/j.jcin.2009.10.003

Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009;2:1248-59 [20129552] 10.1016/j.jcin.2009.10.003

TAXUS IV (diabetics), 2005:

Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-9 [15837245]

TAXUS V (all patients), 2005:

Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23 [16160130]

TAXUS V (diabetics), 2005:

Ellis SG TAXUS V trial global results: expanding the randomizeddata 2005 American College of CardiologyAnnual Scientific Session

TAXUS V small vessels sub groups, 0:

Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23 [16160130]

TAXUS VI, 2005:

Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13 [16286586]

Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Buellesfeld L, Koglin J, Russell ME TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007;28:2578-82 [17938126]

Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Joshi A, Mascioli S TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention 2009;4:572-7 [19378676]

TAXUS VI (diabetics), 2005:

Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13 [16286586]

BASKET-SAVAGE, 0:

ongoing trial NCT00595647

ASPECT, 2003:

Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45 [12700373]

DELIVER, 2004:

ONeill WW, Knopf W, Lansky A, Fitzgerald P, Mahaffey K. Randomized comparison of paclitaxel-coated versus metallic stentsfor treatment of coronary lesions American College of CardiologyScientific Session, March, 2003

Knopf W, ONeill WW, Lansky A, Fitzgerald P, Mahaffey KE Randomized comparison of paclitaxel-coated versus metallicstents for treatment of coronary lesions TranscatheterCardiovascular Therapeutics Annual Meeting, September, 2003

Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WW Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004 Apr 27;109:1948-54 [15078794]

ELUTES, 2004:

Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93 [14744971]

PATENCY, 2002:

unpublished

Heldman A, Farhat N, Fry E, et al.b Paclitaxel-eluting stent for cytostatic prevention of restenosis: the PATENCY Study Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002

BASKET-PROVE (SES), 2010:

Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. N Engl J Med 2010 Nov 16;: [21080780] 10.1056/NEJMoa1009406

C-SIRIUS, 2004:

Schampaert E, Cohen EA, Schlter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5 [15028375]

DEBATER (SES vs BMS), 2009:

DECODE, 2005:

unpublished

Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M. Outcomesin diabetic patients with multivessel disease and long lesions: resultsfrom the DECODE study Am J Cardiol 2005; 96 (suppl 7A): 31H

DESSERT, 2008:

Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P, Zoccai GB Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 2008;101:1560-6 [18489933]

DIABETES, 2005:

Sabat M, Jimnez-Quevedo P, Angiolillo DJ, Gmez-Hospital JA, Alfonso F, Hernndez-Antoln R, Goicolea J, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83 [16203930]

Jimnez-Quevedo P, Sabat M, Angiolillo DJ, Alfonso F, Hernndez-Antoln R, SanMartn M, Gmez-Hospital JA, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007;28:1946-52 [17562666]

Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L Am J Cardiol 2009 Feb 1;103:345-9 [19166687]

Daz de la Llera, 2007:

Daz de la Llera LS, Ballesteros S, Nevado J, Fernndez M, Villa M, Snchez A, Retegui G, Garca D, Martnez A Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007;154:164.e1-6 [17584571]

E-SIRIUS, 2003:

Schofer J, Schlter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9 [14550694]

GISSOC II, 2010:

Rubartelli P, Petronio AS, Guiducci V, Sganzerla P, Bolognese L, Galli M, Sheiban I, Chirillo F, Ramondo A, Bellotti S Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. Eur Heart J 2010;: [20566487] 10.1093/eurheartj/ehq199

Kochiadakis, 2007:

Kochiadakis GE, Marketou ME, Arfanakis DA, Sfiridaki K, Skalidis EI, Igoumenidis NE, Hamilos MI, Kolyvaki S, Chlouverakis G, Kantidaki E, Castanas E, Vardas PE, Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. Atherosclerosis 2007;194:433-8. [16997310] 10.1016/j.atherosclerosis.2006.08.029

MISSION, 2008:

van der Hoeven BL, Liem S, Jukema JW, et al. Prospectiverandomised trial to evaluate the effi cacy and safety of drug-elutingstents versus barem-metal stents for the treatment of acutemyocardial infarction (the MISSION! intervention study) AnnualScientifi c Meeting of the American Heart Association. Chicago, IL,USA; Nov 1215, 2006.

van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008 Feb 12;51:618-26 [18261680]

Ortolani et al, 2007:

Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F, Silenzi S, Cooke RM, Reggiani ML, Branzi A Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv 2007;69:790-8 [17290437]

Pache et al, 2005:

Pache J, Dibra A, Mehilli J, Dirschinger J, Schmig A, Kastrati A Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8 [15737962]

Pasceri, 2003:

unpublished

Pasceri V, Granatelli A, Pristipino C, et al. A randomized trial of arapamycin-eluting stent in acute myocardial infarction: preliminaryresults TCT 2003. Am J Cardiol 2003;92(Suppl 6A):1L.

PRISON II, 2006:

Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006;114:921-8 [16908768]

RAVEL, 2002:

Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnr F, Falotico R A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80 [12050336]

Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007 Oct 2;50:1299-304 [17903626]

Ravel (diabetics), 2004:

Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, Wietze L, Sousa JE, Serruys PW, Morice MC Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J 2004;25:107-12 [14720526]

RRISC, 2006:

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007 Jul 17;50:261-7 [17631219]

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006 Dec 19;48:2423-31 [17174178]

SCANDSTENT, 2006:

Kelbaek H, Thuesen L, Helqvist S, Klvgaard L, Jrgensen E, Aljabbari S, Saunamki K, Krusell LR, Jensen GV, Btker HE, Lassen JF, Andersen HR, Thayssen P, Galle A, van Weert A The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006;47:449-55 [16412876]

Kelbaek H, Klvgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrm T, Btker HE, Jrgensen E, Saunamki K, Aljabbari S, Thayssen P, Galle A, Jensen GV, Thuesen L Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J Am Coll Cardiol 2008 May 27;51:2011-6 [18498953]

SCANDSTENT (subgroup), 2006:

Kelbaek H, Helqvist S, Thuesen L, Klvgaard L, Jrgensen E, Saunamki K, Krusell LR, Btker HE, Engstrm T, Jensen GV Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. Am Heart J 2006;152:882-6 [17070149] 10.1016/j.ahj.2006.03.028

SCORPIUS, 2007:

Baumgart D. One year results of the SCORPIUS-Trial - a Germanmulticenter investigation on the eff ectiveness of sirolimus-elutingstents in diabetic patients Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics. Washington, DC;Oct 2227, 2006. Abstract 288.

Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Vlker W, Pfannebecker T, Stoll HP, Nickenig G One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007 Oct 23;50:1627-34 [17950142]

SES-SMART, 2004:

Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34 [15585732]

SES-SMARt (diabetics), 2005:

Ortolani P, Ardissino D, Cavallini C, Bramucci E, Indolfi C, Aquilina M, Marzocchi A Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy). Am J Cardiol 2005;96:1393-8 [16275185]

SESAMI, 2007:

Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007;49:1924-30 [17498576]

Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli R Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Results of the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010 Feb 23;55:810-814 [20170821] 10.1016/j.jacc.2009.09.046

SIRIUS, 2003:

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23 [14523139]

Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MB Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Am J Cardiol 2007 Apr 15;99:1044-50 [17437725]

Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-40 [14769686]

Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009 Apr 28;53:1488-97 [19389558] 10.1016/j.jacc.2009.01.050

Novack V, Nguyen MC, Rooney M, Chacko R, Novack L, Pencina M, Apruzzese P, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DE Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. Am J Cardiol 2010 Sep 15;106:774-9 [20816116] 10.1016/j.amjcard.2010.04.039

SIRIUS (diabetics), 2003:

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23 [14523139]

Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MB Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Am J Cardiol 2007 Apr 15;99:1044-50 [17437725]

TYPHOON, 2006:

Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104 [16971716]

BASKET-PROVE, 2008:

ongoing trial

Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C, , Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. Am Heart J 2008;155:609-14. [18371466] 10.1016/j.ahj.2007.11.011

TINOX, 2005:

Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T, Wenaweser P, Togni M, Tller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 2005;111:2617-22 [15883209] 10.1161/CIRCULATIONAHA.104.486647

Moschovitis A, Simon R, Seidenstcker A, Klauss V, Baylacher M, Lscher TF, Moccetti T, Windecker S, Meier B, Hess OM Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. EuroIntervention 2010;6:63-8 [20542799] 10.4244/

ENDEAVOR II, 2006:

Gruberg L. ENDEAVOR II. A randomized comparison of the Endeavor ABT-578 drug-eluting stent with a bare metal stent for coronary revascularization,powerpo http://www.medscape.com/viewarticle/501475

Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006 Aug 22;114:798-806 [16908773]

Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol 2007 Feb;55:1-18 [17287679]

Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, Cutlip D, Popma JJ, Zimetbaum P, Fajadet J, Kuntz RE, Wijns W, Fitzgerald PJ Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007 Sep 1;100:818-23 [17719326]

Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, Kong DF, Anstrom KJ Long-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009 Dec;2:1178-87 [20129543] 10.1016/j.jcin.2009.10.011

TIME, 2001:

Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001;358:951-7 [11583747]

Masson C, Pruvo JP, Meder JF, Cordonnier C, Touz E, De La Sayette V, Giroud M, Mas JL, Leys D Spinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. J Neurol Neurosurg Psychiatry 2004;75:1431-5 [15377691]

Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, Eeckhout E, Erne P, Estlinbaum W, Kuster G, Moccetti T, Naegeli B, Rickenbacher P Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289:1117-23 [12622581]

AVERT, 1995:

Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators N Engl J Med 1999;341:70-6 [10395630]

Dakik, 1998:

Dakik HA, Kleiman NS, Farmer JA, He ZX, Wendt JA, Pratt CM, Verani MS, Mahmarian JJ Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study Circulation 1998;98:2017-23 [9808599]

MASS II, 2007:

Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease Circulation 2007;115:1082-9 [17339566] 10.1161/CIRCULATIONAHA.106.625475

Hueb W, Soares PR, Gersh BJ, Csar LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JA The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004;43:1743-51 [15145093]

Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122:949-57 [20733102] 10.1161/CIRCULATIONAHA.109.911669

COURAGE, 2007:

Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 Apr 12;356:1503-16 [17387127]

ALKK, 2003:

Zeymer U, Uebis R, Vogt A, Glunz HG, Vhringer HF, Harmjanz D, Neuhaus KL Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausrzte Circulation 2003;108:1324-8 [12939210] 10.1161/01.CIR.0000087605.09362.0E

Hambrecht, 2004:

Hambrecht R, Walther C, Mbius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler G Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial Circulation 2004;109:1371-8 [15007010] 10.1161/01.CIR.0000121360.31954.1F

Bech, 2001:

Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial Circulation 2001;103:2928-34 [11413082]

ISCHEMIA, :

ongoing trial

CRISTAL, 0:

RIBS-II, 2008:

Alfonso F, Prez-Vizcayno MJ, Hernndez R, Bethencourt A, Mart V, Lpez-Mnguez JR, Angel J, Iiguez A, Mors C, Cequier A, Sabat M, Escaned J, Jimnez-Quevedo P, Bauelos C, Surez A, Macaya C Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol 2008 Nov 11;52:1621-7 [18992651]

FEMH-93005, 0:

ongoing trial NCT00190099

DEDICATION, 2008:

Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klvgaard L, Kaltoft A, Andersen B, Thuesen H, Engstrm T, Btker HE, Saunamki K, Krusell LR, Jrgensen E, Hansen HH, Christiansen EH, Ravkilde J, Kber L, Kofoed KF, Terkelsen CJ, Lassen JF Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008 Sep 9;118:1155-62 [18725489]

Kaltoft A, Kelbk H, Thuesen L, Lassen JF, Clemmensen P, Klvgaard L, Engstrm T, Btker HE, Saunamki K, Krusell LR, Jrgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Kber L, Kofoed KF, Terkelsen CJ, Helqvist S Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment

Elevation Myocardial Infarction 3-Year Follow-Up of the Randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010 Jun 14;: [20688033] 10.1016/j.jacc.2010.05.009

PASEO, 2009:

Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv 2009 Jun;2:515-23 [19539255]

Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation 2009;120:964-72 [19720939]

ISAR-CABG, 0:

ongoing trial NCT00611910

GENIUS-STEMI, 2009:

Cervinka A Randomized Comparison of Genous Stent Versus Chromium-Cobalt Stent for Treatment of ST-Elevation Myocardial Infarction: A 6-Month Clinical, Angiographic, and IVUS Follow-up: GENIUS-STEMI trial ACC.09/i2, Orlando, FL, March 2009

TRIAS-Low-Risk, 0:

ongoing trial

Nordic Bifurcation Stent Technique Study, 0:

ongoing trial NCT00292305

FOCUS, 0:

ongoing trial NCT00485004

SISR, 2007:

Reynolds MR, Pinto DS, Shi C, Walczak J, Berezin R, Holmes DR, Cohen DJ, Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. Am Heart J 2007;154:1221-7. [18035097] 10.1016/j.ahj.2007.07.033

Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006;295:1264-73 [16531619]

SYNTAX, 2009:

Lee TH, Hillis LD, Nabel EG CABG vs. stenting–clinical implications of the SYNTAX trial. N Engl J Med 2009 Feb 19;360:e10 [19228613] 10.1056/NEJMp0900462

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Sthle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009 Mar 5;360:961-72 [19228612] 10.1056/NEJMoa0804626

Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010;55:1067-75 [20079596] 10.1016/j.jacc.2009.09.057

SYNTAX (diabetic), 2010:

Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010;55:1067-75 [20079596]

FREEDOM, 2012:

Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov Strategies for Multivessel Revascularization in Patients with Diabetes. N Engl J Med 2012 Nov 4;: [23121323] 10.1056/NEJMoa1211585

Hong, 2005:

Hong SJ, Lim DS, Seo HS, Kim YH, Shim WJ, Park CG, Oh DJ, Ro YM Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. Catheter Cardiovasc Interv 2005;64:75-81 [15619278]

VA CARDS, 0:

ongoing trial NCT00326196

ARTS, 2001:

Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533-8 [11479249]

de Feyter PJ, Serruys PW, Unger F, Beyar R, de Valk V, Milo S, Simon R, Regensburger D, Crean PA, McGovern E, van den Heuvel P, van Cauwelaert C, Penn I, Tyers GF, Lindeboom W Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina. Circulation 2002;105:2367-72 [12021222]

Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, Lindeboom W, Backx B Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114-20 [14993134]

Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schnberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24 [11297702]

Unger F, Serruys PW, Yacoub MH, Ilsley C, Paulsen PK, Nielsen TT, Eysmann L, Kiemeneij F Revascularization in multivessel disease: comparison between two-year outcomes of coronary bypass surgery and stenting. J Thorac Cardiovasc Surg 2003;125:809-20 [12698143]

CARDia (PCI), 2008:

Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010 Feb 2;55:432-40 [20117456] 10.1016/j.jacc.2009.10.014

ERACI II, 2003:

Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, Vogel D, Grinfeld R, Delacasa A, Garrido M, Oliveri R, Mele E, Palacios I, O'Neill W Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001;37:51-8 [11153772]

Rodriguez A, Rodrguez Alemparte M, Baldi J, Navia J, Delacasa A, Vogel D, Oliveri R, Fernndez Pereira C, Bernardi V, O'Neill W, Palacios IF Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. Heart 2003;89:184-8 [12527674]

LEMANS, 2002:

Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, Bialkowska B, Dudek D, Gruszka A, Zurakowski A, Milewski K, Wilczynski M, Rzeszutko L, Buszman P, Szymszal J, Martin JL, Tendera M Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 2008;51:538-45 [18237682]

MASS II, 2007:

Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007 Mar 6;115:1082-9 [17339566]

Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122:949-57 [20733102] 10.1161/CIRCULATIONAHA.109.911669

Myoprotect, 2004:

Pohl T, Giehrl W, Reichart B, Kupatt C, Raake P, Paul S, Reichenspurner H, Steinbeck G, Boekstegers P Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter Cardiovasc Interv 2004;62:323-30 [15224298] 10.1002/ccd.20060

SOS, 2002:

Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002;360:965-70 [12383664]

Stables RH Design of the 'Stent or Surgery' trial (SoS): a randomized controlled trial to compare coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multi-vessel coronary artery disease. Semin Interv Cardiol 1999;4:201-7 [10738353]

Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, Weintraub WS Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation 2003;108:1694-700 [12975252]

Zhang Z, Weintraub WS, Mahoney EM, Spertus JA, Booth J, Nugara F, Stables RH, Vaccarino V Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). Am J Cardiol 2004;93:404-9 [14969611]

Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, Stables RH Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008;118:381-8 [18606919]

Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, Stables RH Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008 Jul 22;118:381-8 [18606919]

Cisowski, 0:

PLATINUM, 2011:

Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary Stent The PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) Trial. J Am Coll Cardiol 2011 Mar 17;: [21470815] 10.1016/j.jacc.2011.02.016

RESOLUTE All comers, 2010:

Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Dimario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. N Engl J Med 2010 Jun 16;: [20554978] 10.1056/NEJMoa1004130

Silber S, Windecker S, Vranckx P, Serruys PW Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011 Apr 1;: [21459430] 10.1016/S0140-6736(11)60395-4

TWENTE, 2012:

von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Sad SA, Kleijne MA, Sen H, Lwik MM, van der Palen J, Verhorst PM, de Man FH A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients: The TWENTE Trial. J Am Coll Cardiol 2012 Feb 9;: [22341737] 10.1016/j.jacc.2012.01.008

von Birgelen C, van der Heijden LC, Basalus MW, Kok MM, Sen H, Louwerenburg HW, van Houwelingen KG, Stoel MG, de Man FH, Linssen GC, Tandjung K, Dogge Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2017;: [28114618]

Diegeler, 2002:

Diegeler A, Thiele H, Falk V, Hambrecht R, Spyrantis N, Sick P, Diederich KW, Mohr FW, Schuler G Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med 2002;347:561-6 [12192015]

Diegeler A, Spyrantis N, Matin M, Falk V, Hambrecht R, Autschbach R, Mohr FW, Schuler G The revival of surgical treatment for isolated proximal high grade LAD lesions by minimally invasive coronary artery bypass grafting. Eur J Cardiothorac Surg 2000;17:501-4 [10814909]

Drenth, 2002:

Drenth DJ, Veeger NJ, Grandjean JG, Mariani MA, van Boven AJ, Boonstra PW Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? Eur J Cardiothorac Surg 2004;25:567-71 [15037273]

Drenth DJ, Veeger NJ, Winter JB, Grandjean JG, Mariani MA, Boven van AJ, Boonstra PW A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. J Am Coll Cardiol 2002;40:1955-60 [12475455]

Drenth DJ, Winter JB, Veeger NJ, Monnink SH, van Boven AJ, Grandjean JG, Mariani MA, Boonstra PW Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months' angiographic and clinical follow-up of a prospective randomized study. J Thorac Cardiovasc Surg 2002;124:130-5 [12091818]

Grip, 2001:

Grip L, Wahrborg P, Odell A, Albertsson P, Berglin E, Brandrup- Coronary artery bypass beating heart surgery with LIMA graft, versus coronary angioplasty with stent for patients with single left anterior descending artery - a pilot study European Heart Journal 2001;22 (Suppl):597

Kim, 2005:

Kim JW, Lim DS, Sun K, Shim WJ, Rho YM Stenting or MIDCAB using ministernotomy for revascularization of proximal left anterior descending artery? Int J Cardiol 2005;99:437-41 [15771925]

SIMA, 2000:

Goy JJ, Kaufmann U, Goy-Eggenberger D, Garachemani A, Hurni M, Carrel T, Gaspardone A, Burnand B, Meier B, Versaci F, Tomai F, Bertel O, Pieper M, de Benedictis M, Eeckhout E A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc 2000;75:1116-23 [11075740]

OCTOSTENT, 2003:

Eefting F, Nathoe H, van Dijk D, Jansen E, Lahpor J, Stella P, Suyker W, Diephuis J, Suryapranata H, Ernst S, Borst C, Buskens E, Grobbee D, de Jaegere P Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation 2003;108:2870-6 [14656913]

van Dijk D, Nierich AP, Eefting FD, Buskens E, Nathoe HM, Jansen EW, Borst C, Knape JT, Brede JJ, Robles de Medina EO, Grobbee DE, Diephuis JC, de Jaegere PP The Octopus Study: rationale and design of two randomized trials on medical effectiveness, safety, and cost-effectiveness of bypass surgery on the beating heart. Control Clin Trials 2000;21:595-609 [11146152]

Costar II, 2008:

Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008 Apr 22;51:1543-52 [18420096]

Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. J Invasive Cardiol 2008;20:335-41 [18599890]

COSTAR II diabetic (sub group), 2008:

Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. J Invasive Cardiol 2008;20:335-41 [18599890]

COMPARE, 2009:

Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010 Jan 16;375:201-9 [20060578] 10.1016/S0140-6736(09)62127-9

Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice The COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE? stent in all-comers: a randomized open label trial) Trial. J Am Coll Cardiol 2011 Apr 15;: [21514083] 10.1016/j.jacc.2011.02.023

SPIRIT II, 2006:

unpublished

Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hbert K, Sudhir K, Boland J, Huber K, Garcia E, Te Riele JA 3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions The SPIRIT II Trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009 Dec;2:1190-8 [20129545] 10.1016/j.jcin.2009.10.002

Onuma Y, Tanimoto S, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carri D, Thuesen L, Dorange C, Miquel-Hebert K, Veldhof S, Serruys PW Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. Catheter Cardiovasc Interv 2010;76:634-42 [20690152] 10.1002/ccd.22541

SPIRIT III, 2008:

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ, , Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13. [18430909] 10.1001/jama.299.16.1903

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL Circulation 2009;119:680-6 [19171853]

Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention 2010;6:437-46 [20884430] 10.4244/EIJ30V6I4A75

SPIRIT III (small vessel subgroup), 2009:

Hermiller JB, Fergus T, Pierson W, Su X, Sood P, Sudhir K, Stone GW Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. Am Heart J 2009 Dec;158:1005-10 [19958868] 10.1016/j.ahj.2009.09.018

SPIRIT IV, 2010:

Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009;158:520-526.e2 [19781409]

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010 May 6;362:1663-74 [20445180] 10.1056/NEJMoa0910496

Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010;56:2084-9 [21144968] 10.1016/j.jacc.2010.10.006

Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents 2-Year Follow-Up From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV Trial. J Am Coll Cardiol 2011 Apr 15;: [21514084] 10.1016/j.jacc.2011.02.022

5 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
biodegradable polymer sirolimus-eluting stent vs durable polymer everolimus-eluting stent			
BIOFLOW-V [NCT02389946] n=NA follow-up:	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent	patients aged 18 years or older with chronic stable coronary artery disease or acute coronary syndromes undergoing percutaneous coronary intervention	Switzerland
Endeavor stent and three months of DAPT vs standard 12-month DAPT and other DES			
RESET [NCT01145079] n=NA follow-up:	-	-	

More details and results :

- antiplatelets drug for percutaneous coronary intervention in all type of patients at http://www.trialresultscenter.org/go-Q389
- bioresorbable vascular scaffold for percutaneous coronary intervention in all type of patients at http://www.trialresultscenter.org/go-Q668

References

BIOFLOW-V, 0:

Pilgrim T, Heg D, Roffi M, Tller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jni P, Windecker S Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014 Dec 13;384:2111-22 [25189359]

RESET, :

Hong M-K A new strategy for discontinuation of dual antiplatelet therapy: real safety and efficacy of 3-month dual antiplatelet therapy following zotarolimuseluting stent implantation: RESET trial Presented at: American College of Cardiology Scientific Session; 2012, March 24; Chicago, IL

6 carotid stenosis

Trial	Treatments	Patients	Trials design and methods
carotid artery stenting vs medical treatment			
SAMMPRIS , 2011 [NCT00576693] n=224/227 follow-up: 11.9 months	aggressive medical management plus percutaneous transluminal angioplasty and stenting versus aggressive medical management alone	patients who had a recent transient ischemic attack or stroke attributed to stenosis of 70 to 99% of the diameter of a major intracranial artery	Parallel groups open
carotid artery stenting vs surgery			
Leicester (Naylor) , 1998 n=11/12 follow-up: 65279;1 month	Self-expanding Wallstent versus surgery	patients with focal carotid territory symptoms and severe ICA stenosis (>70%)	Parallel groups open
WALLSTENT (Alberts) , 2001 n=107/112 follow-up: 12 months	-	-	Parallel groups open
CAVATAS-CEA , 2001 [ISRCTN01425573] n=251/253 follow-up: 36 months (4y)	Pre-1994: PTA only after 1994: Wallstent, Streker, Palmaz versus carotid endarterectomy	patients of any age with symptomatic or asymptomatic carotid artery stenosis suitable for surgery	Parallel groups open
Kentucky A (Brooks) , 2001 n=53/51 follow-up: 48 months	Wallstent versus surgery	patients presenting with cerebrovascular ischemia ipsilateral to carotid stenosis	Parallel groups open
Kentucky B (Brooks) , 2004 n=43/42 follow-up: 48 months	Wallstent, Dynalink versus carotid endarterectomy	patients with asymptomatic carotid stenosis of more than 80% were selected	Parallel groups open
SAPPHIRE (yadav) , 2004 n=167/167 follow-up: 36 months	Smart or Precise (self-expanding nitinol stent)age/pj versus surgery	patients with coexisting conditions that potentially increased the risk posed by endarterectomy and who had either a symptomatic carotid-artery stenosis of at least 50 percent of the luminal diameter or an asymptomatic stenosis of at least 80 percent	Parallel groups open
EVA-3S (Mas) , 2000 n=261/259 follow-up: 6 months	various stent versus endarterectomy	patients with a symptomatic carotid stenosis of at least 60%	Parallel groups open
SPACE , 2000 n=607/589 follow-up: 1 month	carotid-artery stenting (Carotid Wallstent; Precise; Acculink) versus Carotid endarterectomy	patients with symptomatic carotid-artery stenosis within 180 days of transient ischaemic attack or moderate stroke (modified Rankin scale score of <or =3)	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
TESCAS-C (Ling) , 2006 n=NA follow-up: 6 months	-	-	Parallel groups open
BACASS (Hoffman) , 2006 n=NA follow-up: 45 months	stent versus CEA	patients with symptomatic carotid stenosis >70%	Parallel groups open
Steinbauer , 2008 n=43/44 follow-up: 65 months	carotid artery stenting versus Carotid endarterectomy	-	Parallel groups
ICSS , 2010 [ISRCTN25337470] n=855/858 follow-up: 120 days	carotid artery stenting versus endarterectomy	patients with symptomatic carotid stenosis of greater than 50% within last six months	Parallel groups open Europe, Autralia, New Zealand, Canada
CREST , 2010 [NCT00004732] n=2502 follow-up: 2.5y	carotid artery stenting (with distal-protection) versus carotid endarterectomy	patients with both asymptomatic and symptomatic extracranial carotid stenosis	Parallel groups open US, Canada
SPACE 2 *ongoing* n=NA	-	-	
ACST-2 *ongoing* [NCT00883402] n=NA follow-up: 10 years	Carotid Artery Stenting versus Carotid endarterectomy	patients with asymptomatic carotid artery narrowing in whom prompt physical intervention is thought to be needed, but there there is still substantial uncertainty shared by patient and doctor about whether surgery or stenting is the more appropriate choice	Parallel groups open
ACT I *ongoing* [NCT00106938] n=NA follow-up:	-	-	
Agostoni *ongoing* n=NA	-	-	
Link *ongoing* n=NA	-	-	

More details and results :

- endovascular treatment for carotid stenosis in all type of stenosis at http://www.trialresultscenter.org/go-Q164

References

SAMMPRIS, 2011:

Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL, Torbey MT, Zaidat Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis. N Engl J Med 2011 Sep 7;: [21899409] 10.1056/NEJMoa1105335

Leicester (Naylor), 1998:

Naylor AR, Bolia A, Abbott RJ, Pye IF, Smith J, Lennard N, Lloyd AJ, London NJ, Bell PR Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J Vasc Surg 1998;28:326-34 [9719328]

WALLSTENT (Alberts), 2001:

Alberts MJ Results of a multicentre prospective randomized trial of carotid artery stenting vs carotid endarterectomy [ABSTRACT] Stroke 2001;32:325.

CAVATAS-CEA, 2001:

Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet 2001;357:1729-37 [11403808]

Ederle J, Bonati LH, Dobson J, Featherstone RL, Gaines PA, Beard JD, Venables GS, Markus HS, Clifton A, Sandercock P, Brown MM Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol 2009 Aug 28;: [19717345]

Bonati LH, Ederle J, McCabe DJ, Dobson J, Featherstone RL, Gaines PA, Beard JD, Venables GS, Markus HS, Clifton A, Sandercock P, Brown MM Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol 2009 Aug 28;: [19717347]

Kentucky A (Brooks), 2001:

Brooks WH, McClure RR, Jones MR, Coleman TC, Breathitt L Carotid angioplasty and stenting versus carotid endarterectomy: randomized trial in a community hospital. J Am Coll Cardiol 2001;38:1589-95 [11704367]

Kentucky B (Brooks), 2004:

Brooks WH, McClure RR, Jones MR, Coleman TL, Breathitt L Carotid angioplasty and stenting versus carotid endarterectomy for treatment of asymptomatic carotid stenosis: a randomized trial in a community hospital. Neurosurgery 2004;54:318-24; discussion 324-5 [14744277]

SAPPHIRE (yadav), 2004:

Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Whitlow P, Strickman NE, Jaff MR, Popma JJ, Snead DB, Cutlip DE, Firth BG, Ouriel K Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493-501 [15470212]

Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Ansel G, Strickman NE, Wang H, Cohen SA, Massaro JM, Cutlip DE Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 2008 Apr 10;358:1572-9 [18403765]

EVA-3S (Mas), 2000:

Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP, Larrue V, Livre M, Leys D, Bonneville JF, Watelet J, Pruvo JP, Albucher JF, Viguier A, Piquet P, Garnier P, Viader F, Touz E, Giroud M, Hosseini H, Pillet JC, Favrole P, Neau JP, Du Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660-71 [17050890]

Mas JL, Trinquart L, Leys D, Albucher JF, Rousseau H, Viguier A, Bossavy JP, Denis B, Piquet P, Garnier P, Viader F, Touz E, Julia P, Giroud M, Krause D, Hosseini H, Becquemin JP, Hinzelin G, Houdart E, Hnon H, Neau JP, Bracard S, Onnient Y, Padovani R, Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008;7:885-92 [18774745]

SPACE, 2000:

Ringleb PA, Allenberg J, Brckmann H, Eckstein HH, Fraedrich G, Hartmann M, Hennerici M, Jansen O, Klein G, Kunze A, Marx P, Niederkorn K, Schmiedt W, Solymosi L, Stingele R, Zeumer H, Hacke W 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006;368:1239-47 [17027729]

Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H, Jansen O Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008;7:893-902 [18774746]

TESCAS-C (Ling), 2006:

Ling F, Jiao LQ. Preliminary report of trial of endarterectomy versus stenting for the treatment of carotid atherosclerotic stenosis in China (TESCAS-C).xml HT Chinese Journal of Cerebrovascular Diseases 2006;3(1): 48.*;

BACASS (Hoffman), 2006:

Hoffmann A, Taschner C, Engelter ST, Lyrer P, Rem J, Radue EW, et Carotid artery stenting versus carotid endarterectomy. A prospective, randomised trial with long termfollow up (BACASS). Schweizer Archiv fr Neurologie und Psychiatrie 2006;157:191.

Steinbauer, 2008:

Steinbauer MG, Pfister K, Greindl M, Schlachetzki F, Borisch I, Schuirer G, Feuerbach S, Kasprzak PM Alert for increased long-term follow-up after carotid artery stenting: results of a prospective, randomized, single-center trial of carotid artery stenting vs carotid endarterectomy. J Vasc Surg 2008;48:93-8 [18486419] 10.1016/j.jvs.2008.02.049

ICSS, 2010:

Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010 Feb 25;: [20189239] 10.1016/S0140-6736(10)60239-5

CREST, 2010:

Brott TG, Roubin G, Howard G, et al The Randomized Carotid Revascularization Endarterectomy vs Stenting Trial (CREST): Primary results American Stroke Association International Stroke Conference 2010; February 26, 2010; San Antonio, TX. Abstract 197

Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE, Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL, Silver FL, Mohr JP, Lal BK, Mes Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis. N Engl J Med 2010 May 26;: [20505173] 10.1056/NEJMoa0912321

SPACE 2, 0:

ongoing trial

Reiff T, Stingele R, Eckstein HH, Fraedrich G, Jansen O, Mudra H, Mansmann U, Hacke W, Ringleb P Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy: SPACE2 - a three-arm randomised-controlled clinical trial. Int J Stroke 2009 Aug;4:294-9 [19689759] 10.1111/j.1747-4949.2009.00290.x

ACST-2, 0:

ongoing trial NCT00883402

ACT I, 0:

ongoing trial NCT00106938

Agostoni, 0:

ongoing trial

Link, 0:

ongoing trial

Entry terms: drug-eluting stents, CYPHER, TAXUS, Promus, Xience, Biomatrix, Nobori, Endeavor, Drug-Eluting Stents, Drug Eluting Stents, Drug-Eluting Stent, Drug-Coated Stents, Drug Coated Stents, Drug-Coated Stent, , PCI, sirolimus eluting stent, CYPHER, , biolimus eluting stent, everolimus eluting stent, XIENCE V, Guidant XIENCE V, Abbott XIENCE V, XIENCE 5, zotarolimus eluting stent, Endeavour, Medtronic Endeavour, abciximab, carotid artery stenting, dactinomycin eluting stent, paclitaxel, Anzatax, NSC-125973, NSC 125973, NSC125973, Taxol, Taxol A, Bris Taxol, Paxene, Praxel, 7-epi-Taxol, 7 epi Taxol, Onxol